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Chapter	1	Introduction	
Outlook	
Parkinson’s	disease	(PD)	is	one	of	the	most	common	neurodegenerative	diseases,	second	only	to	
Alzheimer’s	disease	(AD)	in	prevalence.	Approximately	1-2%	of	the	population	older	than	65	years	of	
age	are	affected,	with	prevalence	reaching	4%	by	the	age	of	95	(de	Lau	and	Breteler,	2006).	Age	
adjusted	incidence	rates	are	similar	between	countries	of	Asian	ethnicity	versus	countries	with	
Caucasian	ethnicity	(Asian	versus	Europe	and	the	Americas),	while	African	countries	have	lower	
prevalence,	adjusted	both	for	mortality	and	incidence,	than	in	Europe	or	North	and	South	America	
(de	Lau	and	Breteler,	2006).	As	the	average	age	of	the	population	in	many	developed	and	developing	
nations	increases,	the	number	of	PD	cases	is	also	expected	to	increase	dramatically	in	the	next	two	
decades,	from	approximately	four	million	cases	to	over	nine	million	cases	worldwide	(Dorsey	et	al.,	
2007).		
	
PD	is	a	heterogeneous	disease,	both	genetically	and	clinically.	Physicians	diagnose	PD	based	on	a	
series	of	clinical	characteristics	and	exclusion	criteria	as	developed	by	the	United	Kingdom	Brain	
Bank	(UKBB),	with	the	diagnostic	criteria	focusing	on	motor	symptoms	including	resting	tremor,	
bradykinesia,	and	rigidity	(Gibb	and	Lees,	1988).	In	addition	to	the	motor	symptoms,	non-motor	
symptoms	such	as	hyposmia,	depression,	sleep	disorders,	and	constipation	have	also	proven	useful	
as	prodromal	symptoms	with	predictive	qualities	to	determine	the	progression	of	PD	before	the	
onset	of	motor	symptoms	in	patients	(Witjas	et	al.,	2002,	Schrag	et	al.,	2000).		The	more	recent	
Movement	Disorder	Society	Clinical	Diagnostic	criteria	also	increased	recognition	to	non-motor	
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systems,	while	maintaining	motor	parkinsonism	as	the	central	feature	of	the	disease	(Postuma	et	al.,	
2015).	
	
Technological	advancements	over	the	last	20	years	along	with	the	availability	of	comprehensive	
catalogue	of	genetic	variations	from	multi-ethnic	populations	available	in	various	publically	available	
data	bases	such	as	the	HapMap	project	and	the	1000	Genomes	project	have	enabled	researchers	to	
decipher	the	genetic	landscape	of	complex	diseases	including	PD	(Lander	et	al.,	2001,	Genomes	
Project	et	al.,	2010,	International	HapMap,	2005,	Simon-Sanchez	et	al.,	2009,	Lill,	2016).	The	
development	of	PCR	amplification	allowed	for	the	processing	of	multi-allelic	markers	to	map	disease	
loci	in	families	using	linkage-based	studies.	(Elston,	1998,	Singleton	et	al.,	2003).		This	approach	led	
to	successful	identification	of	a	number	of	genes	involved	in	monogenic	forms	of	PD	(Shulman	et	al.,	
2011).		However,	monogenetic	forms	of	PD	only	explain	a	fraction	of	PD	cases.	Out	of	the	diagnosed	
PD	cases,	approximately	5-10%	of	patients	develop	PD	as	a	result	of	either	autosomal	dominant	or	
autosomal	recessive	forms	of	PD.		In	contrast,	the	development	of	array	based	approaches	led	to	
start	of	genome	wide	association	studies	(GWAS).		GWAS	followed	an	unbiased	approach	in	
identifying	novel	loci	for	a	given	phenotype	(Mullin	and	Schapira,	2015).	This	approach	examines	a	
genome-wide	set	of	genetic	variants	across	individuals	to	identify	loci	associated	with	a	given	trait,	
successfully	leading	to		the	identification	novel	loci	for	PD	(Lill,	2016).		Despite	the	success	of	GWAS,	
the	majority	of	genetic	architecture	still	remains	elusive,	and	thus	indicating	the	complex	genetic	
architecture	of	PD	(Obeso	et	al.,	2017).		The	thesis	presented	herein	aims	to	plug	this	gap	by	
following	a	multi-dimensional	strategy	that	investigates	the	complex	disease	origins	of	PD.		
Scope	of	the	thesis:	
The	scope	of	this	thesis	has	three	broad	sections.	The	first	section,	Chapter	1,	describes	the	current	
status	of	PD	literature,	and	explores	the	possible	avenues	of	influence	on	risk	of	disease	as	the	
literature	currently	stands.	The	second	section,	Chapter	2,	presents	the	original	work	of	the	thesis,	
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the	projects	undertaken	in	investigating	the	varied	risk	factors	of	PD,	consisting	of	parts	1,	2,	and	3.	
Part	3	investigated	the	influence	of	genes	on	possible	cross-phenotype	effect,	by	investigating	the	
effect	of	ataxia	genes	on	PD	risk.	Recent	evidence	has	shown	that	although	the	various	late-onset	
neurodegenerative	diseases	such	as	ataxias,	AD,	and	PD	present	with	clinically	heterogeneous	
characteristics,	for	example	differential	pathogenesis	and	degeneration	of	the	motor	system,	they	
may	have	common	genetic	risk	factors	that	influence	the	predisposition	to	disease	development.	
Previous	clinical	and	pathologic	findings	have	emphasized	the	need	to	evaluate	the	significance	of	
polyglutamine	repeat	expansions	in	PD	worldwide	(Gwinn-Hardy	et	al.,	2001,	Wang	et	al.,	2009).	Of	
particular	interest	is	the	possible	connection	between	SCA	genes,	including	SCA2	(ATXN1),	SCA3	
(ATXN3),	SCA6	(CACNA1A),	and	SCA17	(TBP)	and	their	influence	on	the	probability	of	developing	
idiopathic	PD	(Charles	et	al.,	2007,	Furtado	et	al.,	2004,	Lim	et	al.,	2006,	Kim	et	al.,	2009).	Previous	
studies	have	screened	for	SCA2,	SCA3,	SCA6	and	SCA17	genes	in	cohorts	of	autosomal	dominant	PD	
and	identified	carriers,	suggesting	that	intermediate	repeat	structure	may	influence	the	clinical	
variability	in	autosomal	dominant	forms	of	PD	and	cerebellar	ataxia.	We	address	the	question	of	
possible	risk	due	to	intermediate	polyglutamine	repeats	in	idiopathic	PD.		
Part	2	addresses	the	influence	of	genetic	interaction	by	investigating	how	known	PD	risk-affecting	
variants	encompassing	the	LRRK2	and	PARk16	loci	mediate	each	other	and	thus	in	turn	modulate	
total	disease	risk.	Recent	studies	have	demonstrated	a	functional	interaction	between	the	retromer	
and	lysosomal	pathways	in	PD	pathogenesis,	and	interestingly	two	genes,	namely	LRRK2	and	RAB7L1	
have	shown	to	functionally	interact	(MacLeod	et	al.,	2013).	Studies	have	also	demonstrated	that	
overexpression	of	the	RAB7L1	gene	rescues	the	LRRK2	mutant	phenotype,	thus	suggesting	that	both	
RAB7L1	and	LRRK2	genes	are	bound	together	and	functionally	interact	with	each	other	in	regulating	
neurite	length	both	in	vitro	and	in-vivo	(Chuang	and	Gitler,	2013).	Chapter	4	dealt	with	this	issue	to	
understand	the	impact	of	interaction	in	world-wide	populations	using	the	tagged	single	nucleotide	
polymorphisms	(SNPs)	encompassing	these	two	loci.		
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Part	3	of	the	results	investigated	the	epidemiological	interaction	between	PD	and	diabetes,	a	disease	
of	the	adaptive	immune	system.	As	more	is	learned	about	PD	pathogenesis,	researchers	have	also	
found	evidence	that	the	neuronal	degeneration	may	result	from	destructive	immune	responses.	
There	is	a	compelling	argument	that	PD	pathogenesis	is	modulated	and	influenced	by	the	adaptive	
immune	system	(Surendranathan	et	al.,	2015).	Type	1	Diabetes	Mellitus	(T1DM)	is	also	characterized	
by	an	autoimmune	response,	thereby	destroying	the	body’s	capability	of	insulin	production	(Singh	et	
al.,	2011).	Due	to	the	similarities	in	the	two	diseases	and	their	relationships	to	immune	dysfunction,	
we	utilized	the	largest	German	diabetes	database	to	investigate	possible	differential	disease	
pathogenesis	between	T1DM	patients	with	PD	and	neurologically	normal	T1DM	patients.		
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History	of	Disease	
Parkinson’s	disease	(PD)	was	mentioned	in	medical	writings	as	early	as	Galen’s	documents	(Larner,	
2014).	The	first	unambiguous	description	of	the	disease	is	attributed	to	James	Parkinson,	an	English	
doctor	who	published	in	1817	a	set	of	six	case	studies	titled	“An	Essay	on	the	Shaking	Palsy”	
(Parkinson,	2002).	Parkinson	characterized	the	disease	of	his	namesake,	describing	in	detail	the	
abnormal	posture,	altered	gait,	paralysis,	weakness,	and	resting	tremor	observed	in	his	six	cases,	
focusing	on	the	physical	manifestation	of	the	disease,	with	limited	hypothesis	regarding	its	origins	
(Parkinson,	2002).	Nonetheless,	his	seminal	essay	contains	the	first	definitive	expositions	about	this	
debilitating	neurodegenerative	disease.	In	1912,	Frederic	Lewy	discovered	the	common	presence	of	
protein	bundles	in	the	brains	of	PD	patients,	later	called	“Lewy	bodies”,	advancing	the	pathological	
characterization	of	the	disease	(Rodrigues	e	Silva	et	al.,	2010).	Later	on	in	1997,	Spillantini,	
Trojanowski,	and	Goedert	et	al	found	that	the	main	component	of	Lewy	bodies	is	alpha-synuclein	
(SNCA),	thus	bringing	our	understanding	of	PD	into	modern	times	(Goedert	et	al.,	2017).		
PD	primarily	affects	the	elderly	population,	with	prevalence	at	approximately	1-2%	for	patients	older	
than	65,	rising	to	4%	for	patients	older	than	85	(Brooks,	2012).	Mean	age	of	diagnosis	is	mid	60’s,	
with	range	of	disease	diagnosis	from	the	2nd	to	the	8th	decade	(Baumann,	2012).	The	main	pathology	
of	PD	is	the	defining	loss	of	neurons	in	the	substantia	nigra	pars	compacta	(SNPc),	the	reduction	in	
neurons	leading	to	striatal	dopamine	deficiency	(Obeso	et	al.,	2017).		
Non-motor	symptoms	develop	first,	with	degradation	of	the	olfactory	system,	constipation,	and	
sleep	problems.	Non-motor	symptoms	of	PD	can	be	grouped	into	the	following	categories:	
neuropsychiatric	symptoms,	sleep	disorders,	autonomic	symptoms,	gastrointestinal	symptoms,	and	
sensory	symptoms	(Chaudhuri	et	al.,	2006).	Depression	affects	up	to	45%	of	PD	patients	(Schrag	et	
al.,	2000).	Causes	of	depression	include	both	disease	pathogenesis	and	psychological	reactions	due	
to	the	progressive	debilitation.	Excessive	daytime	sleepiness	and	disruption	of	REM	sleep	is	also	
commonly	observed,	affecting	up	to	50%	of	patients	(Schapira,	2004).	Most	likely,	disease	
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advancement,	levodopa	therapy,	and	nighttime	sleep	disruption	together	cause	the	sleep	disorders	
seen	in	PD	patients	(Schapira,	2004).	Dementia	is	much	more	prevalent	in	PD	cases,	with	patients	6	
times	more	likely	to	develop	dementia	than	in	a	healthy	population,	affecting	approximately	40%	of	
patients	(Titova	et	al.,	2017b).	Constipation,	pathologically	linked	to	loss	of	colonic	and	central	
dopaminergic	neurons,	is	a	common	pro-dromal	PD	symptom	that	has	been	linked	to	PD	prediction	
(Singaram	et	al.,	1995).	Hyposmia,	the	most	common	prodromal	symptom	affecting	up	to	90%	of	
patients,	also	increases	the	risk	of	a	person	receiving	a	PD	diagnosis	within	2	years	follow-up	(Lee	
and	Koh,	2015).		
Further	neuronal	degeneration	causes	the	characteristic	motor	symptoms	of	bradykniesia,	rigidity,	
and	resting	tremor	(Gelb	et	al.,	1999).	Bradykinesia	is	strongly	correlated	with	dopamine	deficiency	
and	is	strongly	related	to	basal	ganglia	disorders	(Berardelli	et	al.,	2001,	Vingerhoets	et	al.,	1997).	
Rigidity,	defined	as	stiff	or	inflexible	muscles,	is	another	primary	motor	symptom,	manifesting	itself	
by	severely	limiting	movement	such	as	turning	or	standing	from	a	seated	position,	or	causing	a	fixed	
or	mask-like	facial	expression.	Often	initially	appearing	as	a	stiff	shoulder,	the	increased	resistance	
that	characterizes	rigidity	goes	on	to	also	affect	locomotion	and	axial	coordination	of	the	trunk.	A	
prospective	study	of	6038	persons	(mean	age	68.5)	found	a	hazard	ratio	of	2.11	relating	the	
presence	of	stiffness	to	the	risk	of	developing	PD	(de	Lau	et	al.,	2006).	Resting	tremors	in	PD	are	
characterized	by	unilateral	onset	in	the	fingers	at	a	frequency	between	4	and	6	Hz,	and	progression	
to	bilateral	symptoms	as	disease	progresses.	In	a	prospective	study	with	autopsy	proven	disease,	
100%	of	autopsy	certified	patients	at	some	point	also	experienced	tremors	(Rajput	et	al.,	1991).	In	
another	study,	Hughes	et	al	found	that	69%	of	patients	exhibited	resting	tremor	at	point	of	disease	
onset,	and	75%	of	patients	experienced	the	symptom	at	some	point	over	the	course	of	the	disease	
(Hughes	et	al.,	1993).	Response	to	levodopa	treatment	is	the	third	tenet	of	PD	characterization,	a	
defining	trait	of	PD	and	used	in	the	determination	of	disease	(Baumann,	2012)	.		
Parkinson’s	disease	staging	system	
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The	traditional	staging	system	of	PD	as	laid	out	by	the	United	Kingdom	Brain	Bank	(UKBB)	diagnostic	
criteria	focuses	on	the	motor	symptoms	of	PD	(Gibb	and	Lees,	1988).	The	important	indications	of	
PD	include	pathological	degeneration	of	the	projection	neurons	of	the	substantia	nigra	pars	
compacta.	The	disease	progression	of	idiopatic	PD	is	well-documented,	with	well-defined	induction	
sites	that	develop	in	a	predicable	sequence	(Gibb	and	Lees,	1988).	The	traditional	disease	
pathogenesis	with	on-set	characterized	by	degeneration	of	dopaminergic	neurons	in	the	substantia	
nigra	has	been	challenged	by	Braak	and	colleagues,	who	developed	from	autopsy	studies	a	PD	
pathogenesis	trajectory	composed	of	a	six-stage	process	with	clearly	defined	induction	sites	of	Lewy-
body	formation	(Braak	et	al.,	2002,	Braak	et	al.,	2003),	with	full	manifestation	of	the	motor	
symptoms	occurring	in	the	last	two	stages,	and	pre-motor	symptoms	dominating	in	the	initial	
staging.	Diagnosis	of	idiopathic	PD	is	relatively	accurate	when	using	the	conventional	criteria	of	
asymmetrical	onset	of	akinesia	rigidity	and	tremor	in	conjunction	with	lack	of	atypical	symptoms	(93	
%)	(Hughes	et	al.,	1993).	However,	atypical	features	such	as	several	early	dementia,	lack	of	response	
to	levodopa,	confusion,	or	early	autonomic	degeneration	was	also	found	in	12%	of	autopsy	
confirmed	idiopathic	PD	cases	(Hughes	et	al.,	1992)	
Genetics	of	PD	
Twin	Studies	
Twin	and	familial	studies	allowed	for	the	studying	of	both	shared	genetic	or	environmental	
components	prior	to	the	“genomics	era”.	Monozygotic	twins	share	complete	genetic	information	
while	dizyogtic	twins	share	approximately	50%	of	their	genetic	information	(Wirdefeldt	et	al.,	
2011b).	Because	both	types	of	twins	share	environmental	and	familial	factors,	one	can	differentiate	
between	the	genetic	inheritability	of	the	disease	versus	the	influence	of	environmental	factors	on	
the	disease.	Twin	studies	compare	the	concordance	rates	in	monozygotic	versus	dizygotic	twins;	a	
higher	rate	of	concordance	in	monozygotic	twins	demonstrates	a	genetic	component	to	the	disease.	
While	cross-sectional	twin	studies	did	not	demonstrate	different	concordance	rates	by	zygosity	in	
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normal	onset	PD	cases,	several	studies	including	the	National	Academy	of	Sciences/National	
Research	Council	World	War	II	veteran	twin	registry	and	the	Swedish	Twin	Registry	found	increased	
concordance	rates	in	early	(before	age	50)	onset	(Wirdefeldt	et	al.,	2011b).		A	prospective	
longitudinal	study	by	Mayo	Clinic	Rochester	also	followed	monozygotic	and	dizygotic	twin	pairs	for	
clinical	PD	and	found	evidence	suggesting	a	substantial	role	in	inheritance	in	sporadic	PD	(Piccini	et	
al.,	1999).	
Autosomal	dominant	forms	of	PD	
SNCA	(PARK1)	
The	first	autosomal-dominant	gene,	SNCA,	was	discovered	in	1997	in	4	separate	families	of	Greek	
and	Italian/American	origins	(Polymeropoulos	et	al.,	1997).	All	families	presented	with	autosomal-
dominant	mode	of	inheritance.	Since	then,	a	number	of	families	have	been	identified	across	
different	populations,	which	led	to	the	identification	of	additional	missense	mutations.	The	SNCA	
mutations	(	A53T,	A30P,	E46K,	G51D,	H50Q,	and	A53E),	located	the	long	arm	of	chromosome	4q21	
(Kalinderi	et	al.,	2016).			
The	different	SNCA	missense	mutations	present	with	a	wide	range	of	clinical	symptoms,	from	
classical	PD	to	atypical	PD	including	severe	autonomic	dysfunction	and	dementia	in	addition	to	
Parkinsonism	(Kalinderi	et	al.,	2016).	Phenotypes	also	differentiate	by	mutations.	The	A53T	mutation	
typically	presenting	with	earlier	age	of	onset	and	rapid	progression	in	addition	to	high	prevalence	of	
psychiatric	and	dementia	symptoms	(Goedert,	2001).	The	A30P	mutation	is	associated	with	milder	
disease	and	later	age	of	onset	(Kruger	et	al.,	1998).	The	E46K	mutation	presents	with	a	phenotype	
more	typical	of	diffuse	Lewy	body	(DLB)	disease	(Zarranz	et	al.,	2004).	A	dosage	effect	has	also	been	
demonstrated	in	the	mutation,	with	duplicates	and	triplicates	showing	earlier	age	of	onset,	more	
rapid	disease	progression,	and	a	higher	prevalence	of	dementia	(Singleton	et	al.,	2003,	Chartier-
Harlin	et	al.,	2004).		SNCA	triplicates	experience	on	average	~10	year	earlier	age	of	onset	as	opposed	
SNCA	duplicates	(Lill	et	al.,	2016).		
	
	
12	
SNCA	is	the	main	component	of	Lewy	bodies,	which	are	one	of	the	characeristic	neuropathological	
biomarkers	of	PD	(Goedert,	2001).	Additionally,	glial	cytoplasmic	inclusions	as	observed	in	multiple	
system	atrophy	(MSA)	have	also	been	shown	to	be	strongly	immunoreactive	for	alpha-synuclein	
(Goedert,	2001).	It	is	hypothesized	that	aggregation	of	the	protein	plays	an	important	role	in	the	
neurodegeneration	seen	in	Lewy	body	diseases	and	MSA.	Mitochrondrial	dysfunction	and	oxidative	
stress	has	also	been	associated	with	mutations	in	SNCA	gene	(Smith	et	al.,	2005).		
The	concentration	of	alpha-synuclein	increases	with	the	number	of	replicates	of	the	gene:	duplicates	
present	with	150%	concentration	of	the	protein,	while	triplicates	present	with	200%	concentration	
of	the	protein	(Farrer	et	al.,	2004).	Point	mutations	of	SNCA	appear	to	lead	to	increased	aggregation	
behavior	of	the	proteins	(Conway	et	al.,	1998).	Synuclein	expression	has	also	been	found	to	be	
substantially	increased	in	PD	patients	versus	neurologically	normal	patients,	with	one	study	
recording	levels	of	on	average	4	times	in	PD	patients	despite	substantial	loss	and	degeneration	of	
the	substantia	nigra	(Chiba-Falek	et	al.,	2006).	The	development	of	alpha-synuclein	filaments	has	
been	hypothesized	to	be	both	necessary	and	sufficient	for	dopamine	nerve	cell	degeneration,	a	
defining	pathology	of	PD	(Goedert,	2001).		
	
LRRK2	(PARK8)	
The	second	autosomal	dominant	gene	discovered	was	LRRK2	(leucine-rich	repeat	kinase	2).	
Appearing	with	much	higher	frequencies	than	SNCA,	the	gene	has	6	confirmed	highly	penetrant	
pathogenic	mutations	(R1441C,	R1441G,	R1441H,	Y1699C,	G2019S,	and	I2020T)	(Healy	et	al.,	2008a,	
Healy	et	al.,	2008b).	The	LRRK2	protein	encodes	a	large	multi-domain	protein	containing	guanosine	
triphosphatase	(GTPase),	kinase,	and	protein-protein	interaction	domains	(Zimprich	et	al.,	2004).	
While	the	exact	function	is	not	known,	emerging	evidence	indicates	that	it	plays	a	role	in	the	
intracellular	signaling	pathways	and	vesicle	formation	and	transport	(Tan	et	al.,	2007).	Widely	
expressed	throughout	the	brain	and	other	systems,	it	has	also	been	the	subject	of	many	functional	
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and	genetic	interaction	studies	that	have	investigated	the	synergistic	interaction	between	itself	and	
the	PARK16	locus	(Chuang	and	Gitler,	2013,	MacLeod	et	al.,	2013).	LRRK2	appears	with	higher	
frequency	than	SNCA,	with	the	G2019S	mutation	exhibiting	frequency	of	up	to	20%	in	Ashkenazi	
Jews	and	40%	in	North	African	Arabs	(Healy	et	al.,	2008a).	Average	frequencies	range	between	5-
15%	in	familial	cases	and	approximately	1%	in	the	general	Caucasian	population	(Berg	et	al.,	2005).	
Penetrance	in	general	is	considered	moderate	due	to	the	large	number	of	neurologically	normal	
individuals	with	the	mutation.		
The	G2019S	mutation	is	of	particular	interest	within	the	LRRK2	loci.	It	is	the	most	common	genetic	
risk	factor	to	date	identified	for	PD	(Bouhouche	et	al.,	2017).	The	G2019S	mutation	is	defined	by	its	
high	penetrance,	between	30%	to	70%	in	certain	familial	populations	(Li	et	al.,	2015,	Goldwurm	et	
al.,	2007).	In	the	African	Berber	population,	where	a	recent	study	found	the	prevalence	among	
autosomal	dominant	patients	at	76%	and	up	to	28%	within	sporadic	patients,	the	clinical	phenotype	
of	the	disease	was	marked	by	less	severe	tremor	but	higher	degree	of	dystonia	and	dyskinesia	and	
sleep	disturbances	(Bouhouche	et	al.,	2017).	The	clinical	phenotype	from	the	Moroccan	study	are	in	
line	with	findings	in	other	clinical	studies	of	LRRK2	associated	PD	(Pont-Sunyer	et	al.,	2017).		
Two	Asian	population-specific	LRRK2	mutations	have	also	been	identified:	G2385R	and	R1628P	(Di	
Fonzo	et	al.,	2006,	Ross	et	al.,	2008).	The	clinical	phenotype	of	LRRK2	patients	is	typical	for	late-
onset	PD,	with	average	age	of	onset	of	59	with	predominant	symptom	of	tremor	(Zimprich	et	al.,	
2004,	Berg	et	al.,	2005).	While	individual	cases	present	non-differentially	from	sporadic	idiopathic	PD	
cases,	LRRK2	PD	cases	as	a	whole	trend	towards	less	severe	disease	pathogenesis	and	lower	rates	of	
dementia	and	psychiatric	symptoms	(Berg	et	al.,	2005).	The	G2019S	kinase	mutation,	the	most	
common	mutation	of	the	LRRK2	domain,	is	at	the	activation	segment	of	the	MAPKKK	domain	of	
LRRK2;	thus	mutations	in	G2019S	alter	the	kinase	activity	of	LRRK2	(Smith	et	al.,	2006).	Mutant	
LRRK2	is	neuronally	toxic	and	has	been	clinically	shown	to	lead	to	neural	degeneration	(Smith	et	al.,	
2006).			
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EIF4G1	(PARK18)	
Genome-wide	analysis	of	a	multi-incident	autosomal-dominant	PD	family	led	to	the	discovery	of	a	
missense	mutation	(R1205H)	in	eukaryotic	translation	initiation	factor	4-gammon	(EIF4G1)	(Chartier-
Harlin	et	al.,	2011).	Linkage	and	disease	segregation	followed	by	sequencing	and	genotype	analysis	
differentially	identified	6	different	missense	mutations	in	affected	patients	with	familial	Parkinson’s	
disease	and	idiopathic	Lewy	body	disease	versus	none	in	control	patients.	Disease	pathogenesis	
appears	to	be	related	to	increased	vulnerability	of	mutant	cells	to	oxidative	stress	and	mitochondrial	
dysfunction	under	duress.	Further	studies	have	found	EIF4G1	to	be	a	very	rare	cause	of	PD,	and	a	
large	scale	study	in	European	cohorts	found	it	to	be	a	benign	variant,	neither	a	common	nor	high-risk	
locus	for	Parkinson’s	disease	(Huttenlocher	et	al.,	2015).	
VPS35	(PARK17)	
Vacuolar	protein	sorting	35	(VPS35)	is	an	autosomal	dominant	PD	gene	discovered	using	whole-
exome	sequencing	(WES)	(Vilarino-Guell	et	al.,	2011,	Zimprich	et	al.,	2011).	Two	groups	both	
positively	identified	a	mutation	(D620N)	in	an	Austrian	and	a	Swiss	kindred	and	it	has	been	
confirmed	by	additional	independent	datasets	that	the	D620N	mutation	of	the	VPS35	gene	is	a	
causal	autosomal	dominant	PD	gene	(Lill,	2016).	The	VPS35	protein	functions	as	part	of	the	
retrograde	transport	of	proteins	from	endosomes	to	the	trans-Golgi	network.	Furthermore,	VPS35	
has	been	found	to	be	active	in	the	dopamine	signaling	pathway,	interaction	with	the	dopamine	
receptor	D1	(Tian	et	al.,	2015,	Tang	et	al.,	2015b).	Accounting	for	approximately	1%	of	PD	cases	
worldwide,	the	clinical	profile	of	VPS35	patients	resembles	typical	sporadic	idiopathic	PD	patients,	
with	average	age	of	onset	of	53	years	and	low	rates	of	psychiatric	and	dementia	symptoms	in	the	
disease	pathogenesis.		
DNJAC13	(PARK21)	
Exome	analysis	within	a	large	North	American	family	identified	the	DNJAC13	mutation.	The	mutation	
was	observed	in	all	case	family	members	of	the	identifying	family,	and	further	genotype	analysis	in	a	
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multi-ethnic	case	control	series	also	identified	the	mutation	in	cases	(Vilarino-Guell	et	al.,	2014).	
Carriers	present	with	late	age	of	onset	and	common	motor	symptoms	(Rajput	et	al.,	2015).	
Pathological	studies	showed	staining	consistent	with	LB	disease.	Preliminary	functional	analysis	
suggests	that	the	mutation	leads	to	difficulties	in	endosomal	and	retromer	trafficking,	a	common	
theme	among	PD	risk-mutations	(Vilarino-Guell	et	al.,	2014).		
	
CHCHD2	(PARK22)	
A	genome	wide	linkage	analysis	followed	by	next-generation	sequencing	on	a	Japanese	family	with	8	
affected	individuals	and	5	unaffected	individuals	identified	the	coiled-coil-helix-coiled-coil-helix	
domain	containing	2	(CHCHD2)	mutation	(Funayama	et	al.,	2015).	Patients	presented	with	late-onset	
autosomal	dominant	PD	and	typical	parkinsonian	symptoms.	CHCHD2	mutations	are	associated	with	
autosomal	dominant	PD	(Funayama	et	al.,	2015).	CHCHD2	belongs	to	a	protein	family	with	small	
proteins	that	localize	in	the	mitochondrial	intermembrane	space	and	are	involved	in	mitochondrial	
respiration.	Disruptions	of	the	CHCHD2	gene	results	cause	disruptions	in	mitochondrial	respiration	
and	oxidative	activity	(Funayama	et	al.,	2015).	However,	functional	studies	are	needed	to	
understand	the	pathophysiology	of	CHCHD2	mutations	within	PD,	and	genetic	studies	in	other	
populations	are	also	need	to	confirm	the	results.		
TMEM230		
Transmembrane	protein	230	(TMEM230)	is	the	most	recent	autosomal-dominant	gene	discovered	is	
TMEM230.	The	controversy	surrounding	it	exemplifies	the	complexity	of	disentangling	the	genetic	
architecture	of	PD.	A	recent	study	in	2016	identified	a	novel	missense	variant	in	TMEM230	within	a	
family	with	northern	European	ancestry	located	in	North	America,	a	gene	that	encodes	a	primarily	
transmembrane	protein	that	localizes	in	synaptic	vesicles	(Deng	et	al.,	2016).	The	same	family	was	
also	used	for	the	identification	of	DNAJC13	(Olszewska	et	al.,	2016).	TMEM230	signal	was	also	found	
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to	overlap	with	VPS35	signal,	indicating	that	perhaps	VPS35	and	TMEM230	share	a	pathogenic	
pathway	that	results	in	defective	synaptic	vesicle	transport.	However,	the	results	have	not	been	
reproduced	since	the	original	study	in	several	large	European	and	Chinese	ancestry	population	
studies	with	sporadic	PD	cases	(Ibanez	et	al.,	2017,	Yan	et	al.,	2017,	Giri	et	al.,	2017).	Further	studies	
are	needed	to	determine	the	validity	of	TMEM230	gene,	but	the	evidence	thus	far	does	not	support	
the	conclusion	that	it	is	a	disease-causing	mutation.		
	
Autosomal	Recessive	Inheritance	
PARKIN	(PARK2)	
PARKIN	was	first	identified	in	Japanese	families.	Its	subsequent	mapping	led	to	the	identification	of	
gene	and	has	been	shown	to	cause	autosomal	recessive	PD	cases.	The	protein	PARKIN	is	an	ubiquitin	
E3	ligase	that	interacts	with	the	ubiquitin-conjugating	enzymes	E2s	to	mark	proteins	for	autophagy	
(Shimura	et	al.,	2000).	Mutations	(including	A574G,	A633T,	C823T,	G235T,	G500A,	C718T,	C1319T),	
including	deletions,	insertions,	and	point	mutations	disrupt	the	function	of	the	protein,	causing	loss	
of	function	of	the	catalytic	activity	of	the	parkin	protein	(Dawson	and	Dawson,	2014,	Foroud	et	al.,	
2003).	PARKIN	is	the	most	common	cause	of	early	onset	PD,	with	average	age	of	onset	at	32	years	
for	the	Caucasian	population	and	accounting	for	50%	of	familial	autosomal	recessive	early	onset	
cases	younger	than	50	years	of	age	(Periquet	et	al.,	2003).	It	accounts	for	0.4-0.7%	of	all	non-familial	
PD	cases	in	general.	Prevalence	of	the	PARKIN	mutation	in	cases	with	onset	younger	than	25	years	
has	been	observed	to	up	to	50%,	while	prevalence	in	the	age	category	30-45	years	is	observed	to	be	
3-7%	(Periquet	et	al.,	2003,	Bonifati	et	al.,	2001).	The	mutation	has	been	observed	in	sporadic	cases	
as	well	as	familial	cases,	and	penetrance	is	observed	to	be	100%	for	homozygous	carriers	or	
compound	heterozygous.	First	observed	in	a	cohort	of	Japanese	families	with	early-onset	autosomal	
recessive	PD,	it	has	since	then	been	seen	in	sporadic	patients	and	in	populations	from	all	ethnic	
origins	(Hattori	et	al.,	1998).		
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PARKIN	was	first	discovered	in	European	and	North	African	families	with	autosomal	recessive	
juvenile	parkinsonism	(Lucking	et	al.,	2000),	and	the	majority	of	PARKIN	mutations	have	been	found	
in	the	early	onset	or	juvenile	cohort	early	on.	However,	subsequent	studies	have	discovered	that	the	
heterozygous	mutations	of	PARKIN	in	normal	age	on	of	onset	patients	and	families	with	pseudo-
dominant	inheritance	patterns	(Sun	et	al.,	2006).	Thus,	the	current	range	of	age	of	onset	for	PARKIN	
mutations	now	range	from	juvenile	to	post-70	years	of	age	(Sun	et	al.,	2006).	New	evidence	suggests	
that	homozygous	and	multiple	heterozygous	mutations	result	in	early	onset	PD	whereas	single	
heterozygous	mutations	result	in	increased	risk	of	late-onset	PD	(Sun	et	al.,	2006).	It	has	also	been	
observed	that	there	is	a	high	frequency	of	heterozygous	mutations	in	the	general	population	(Klein	
et	al.,	2007).	While	their	role	as	risk	factors	is	less	clear,	it	is	hypothesized	that	effect	of	
heterozygous	mutations	on	conferring	PD	phenotype	is	a	result	of	interactions	with	other	genetic,	
epigenetic,	and	environmental	factors	(Klein	et	al.,	2007).		
	
PINK1	(PARK6)	
PINK1	(PTEN-induced	kinase	1)	is	another	autosomal	recessive	PD	gene.	First	discovered	in	two	
Italian	and	one	Spanish	family,	it	was	subsequently	found	to	have	prevalence	rates	between	0.5-9%	
in	the	general	population,	and	3.7%	in	early	onset	PD	(<50	years	of	age)	(Valente	et	al.,	2004,	
Valente	et	al.,	2001).		Autosomal	recessive	mutations	include	G309D,	W437X,	and	L347P	(Beilina	et	
al.,	2005).	
The	clinical	profile	of	PINK1	is	similar	to	that	of	homozygous	PARKIN,	with	earlier	onset	paired	with	
slower	disease	progression	(Bonifati	et	al.,	2005,	Li	et	al.,	2005).	Heterozygous	mutations	of	PINK1	
(such	as	A339T,	Y431H,	N451S,	C575R)	showed	a	similar	clinical	profile	to	idiopathic	PD	regarding	
age	of	onset,	asymmetrical	motor	degeneration,	and	L-dopa	responsive	(Gandhi	et	al.,	2006).	PINK1	
patients,	however,	show	increased	incidences	of	psychiatric	disorders	such	as	anxiety	and	
depression	(Bonifati,	2012).		
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The	pathology	of	PINK1	cases	is	relatively	unestablished,	however,	Lewy	bodies	typical	for	PD	was	
found	in	the	few	cases	that	were	investigated	(Gandhi	et	al.,	2006).	The	PINK1	protein	is	found	in	the	
mitochondrial	membranes	of	cells	across	all	organ	systems,	not	just	limited	to	the	brain,	and	it	plays	
a	role	in	the	mitochondrial	response	to	cellular	and	oxidative	stress	and	mitochondrial	quality	
control	(Valente	et	al.,	2004).	Mutations	and	deletions	to	the	gene	decreases	the	functional	ability	of	
the	protein.	Like	PARKIN,	PINK1	has	highly	penetrant,	with	homozygous	and	compound	
heterozygous	mutation	carriers	showing	100%	penetrance	(Li	et	al.,	2005).		
DJ1	(PARK7)	
DJ1	is	an	autosomal	recessive	gene	identified	using	kindred	families	(one	Dutch	and	one	Italian	
family)(Bonifati	et	al.,	2003).	It	accounts	for	0.4%	of	early	onset	cases	(<50	years),	and	shows	similar	
disease	pathogenesis	profile	to	PINK1	and	PARKIN	(Bandopadhyay	et	al.,	2004).	Unlike	PARKIN	and	
PINK1,	it	is	theorized	that	DJ1	is	involved	in	the	mechanism	to	protect	neurons	from	oxidative	stress	
(Takahashi-Niki	et	al.,	2004).	Originally	identified	through	a	point	mutation	and	a	large	deletion	
(both	homozygous),	the	list	of	known	DJ1	mutations	now	comprise	of	several	splice-site	mutations,	
missense	mutations	and	exonic	deletions	(Schulte	and	Gasser,	2011,	Abou-Sleiman	et	al.,	2003).	The	
phenotype	for	DJ1	patients	is	similar	to	other	autosomal	recessive	disease	pathogenesis,	with	earlier	
than	average	onset	(20-40	years)	and	slower	progression	(Bonifati	et	al.,	2003,	van	Duijn	et	al.,	
2001).	Some	patients	have	also	presented	with	more	psychiatric	symptoms,	shorter	stature,	and	
brachydactyly,	and	one	family	in	addition	presented	with	dementia	and	amyotrophic	lateral	sclerosis	
(AML)	(Annesi	et	al.,	2005).		
ATP13A2	(PARK9)	
This	mutation	related	to	juvenile	onset	Parkinsonism	was	first	found	in	a	Jordanian	consanguineous	
family	with	Kufor-Rakeb	disease	(PARK9)	with	Parkinsonism	and	dystonia	(Najim	al-Din	et	al.,	1994).	
Further	studies	used	linkage	analysis	to	confirm	the	mutation	in	a	pedigree	from	Chile	(Ramirez	et	
al.,	2006).	A	study	with	46	patients	with	juvenile	onset	familial	or	sporadic	PD	also	confirmed	the	
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findings	and	discovered	additional	novel	missense	mutations	of	the	same	coding	region	(Di	Fonzo	et	
al.,	2007).	The	ATP13A2	gene	encodes	a	lysosomal	protein	active	in	the	family	of	transmembrane	
active	transporters	(Di	Fonzo	et	al.,	2007).	There	is	increasing	evidence	of	the	importance	of	
lysosomes	and	cellular	waste	transport,	in	particular	of	alpha-synuclein,	in	playing	a	central	role	in	
PD	pathogenesis	and	etiology	(Ramirez	et	al.,	2006).		
FBX07	(PARK15)	
Mutations	in	the	F-box	only	protein	7		(FBXO7)	gene	causes	autosomal	recessive	juvenile	onset	
Parkinsonism	with	pyramidal	disturbance	(PARK15)	(Bonifati,	2012).	The	mutation	of	the	gene	was	
characterized	using	a	Dutch	and	an	Italian	family,	and	the	protein	isoforms	were	confirmed	to	be	
differentially	expressed	between	affected	PARK15	patients	and	WT	proteins	(Di	Fonzo	et	al.,	2009).	
Age	of	onset	was	in	the	teenage	years,	and	patients	presented	with	classic	motor	symptoms	in	
additional	to	dysphagia	and	slowed	saccades	that	responded	to	levodopa	treatment	(Di	Fonzo	et	al.,	
2009).		Functionally,	it	has	been	demonstrated	that	FBXO7	mutations	disrupts	mitophagy,	leading	to	
toxic	aggregation	of	the	FBXO7	protein	in	the	mitochondria	and	decreasing	cellular	(and	
dopaminergic	cellular)	viability	(Zhou	et	al.,	2015).		
DNAJC6	(PARK19)	
DNAJC6	is	an	autosomal	recessive	PD	gene	also	discovered	using	WES	methods	on	two	symptomatic	
brothers	from	a	consanguineous	family	in	Palestine	(Elsayed	et	al.,	2016,	Edvardson	et	al.,	2012).	
Additional	familial	studies	found	the	mutation	in	2	other	juvenile	onset	families,	confirming	the	
mutation	(Elsayed	et	al.,	2016).	Average	age	of	onset	for	DNAJC6	PD	patients	with	atypical	
symptoms	is	10	years	from	the	7	cases	across	3	families	(range	7-11),	while	carriers	of	DNAJC6	
mutations	with	typical	PD	symptoms	had	an	average	age	of	onset	of	31	years	(Koroglu	et	al.,	2013,	
Olgiati	et	al.,	2016).	It	is	hypothesized	that	DNAJC6	encodes	a	protein	auxilin	that	is	important	for	
vesicle	trafficking,	thus	suggesting	that	PD	pathology	is	strongly	affected	by	this	cellular	
mechanism(Eisenberg	and	Greene,	2007).		
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SYNJ1	(PARK20)	
This	novel	missense	mutation	in	SYNJ1	is	the	most	recent	discovery	of	an	autosomal	recessive	gene	
causing	Parkinsonism.	It	has	been	reported	in	Italian,	Iranian,	and	Indian	consanguineous	families	
with	autosomal	recessive	juvenile	Parkinsonism	(Quadri	et	al.,	2013,	Krebs	et	al.,	2013,	Kirola	et	al.,	
2016).	While	the	mutations	are	rare,	the	mutation	discovered	in	the	Indian	family	was	absent	in	570	
additional	PD	samples,	the	gene	is	highly	conserved	across	species	and	missense	mutations	are	
highly	damaging.	SYNJ1	encodes	a	phosphatase	highly	expressed	in	brain	nerve	terminals	and	
facilitates	endocytosis	in	the	adult	brain;	it	also	interacts	with	proteins	responsible	for	signaling,	
actin	nucleations,	and	synaptic	vesicle	recycling	(Kirola	et	al.,	2016).	It	has	also	been	implicated	in	
Alzheimer’s	disease	and	Down	syndrome,	with	higher	levels	reported	in	patient	brains	versus	
healthy	controls	(Voronov	et	al.,	2008,	McIntire	et	al.,	2012).		
VPS13C	(PARK23)	
VPS13C	is	an	autosomal	recessive	early-onset	PD	gene	that	is	associated	with	early-onset	
parkinsonism	defined	by	severe	disease	with	rapid	disease	progression	and	cognitive	decline	(Lesage	
et	al.,	2016).	It	was	first	discovered	using	whole-exome	sequencing	in	conjunction	with	whole-exome	
linkage	mapping	using	a	patient	population	with	early-onset	non-familial	and	familial	PD	across	
European,	North	African,	Turkish,	and	Lebanese	origins	(Lesage	et	al.,	2016).	The	three	subjects	in	
which	the	mutation	was	discovered	all	presented	with	Levodopa-responsive	parkinsonism	marked	
by	accelerated	degeneration.	Disease	pathology	also	showed	Lewy	body	disease	in	the	brain.	The	
VPS13C	silencing	mutation	is	associated	with	changes	to	the	mitochondrial	function,	namely	
decreased	membrane	potential,	increased	mitochondrial	fragmentation,	and	increased	cellular	
respiration	(Lesage	et	al.,	2016).			
Candidate	gene	studies	
Discovery	of	the	aforementioned	genes	occurred	through	a	variety	of	different	genetic	methods,	in	
step	with	the	technological	status	of	genetic	studies	at	a	given	time.	The	earliest	of	the	genetic	
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studies	used	the	candidate	gene	approach.	Candidate	gene	studies	use	preselected	groups	of	genes	
in	case-control	studies	to	determine	if	there	exists	correlation	between	the	gene(s)	and	the	disease	
factor.	This	early	genetic	study	design	identified	the	first	set	of	risk	genes,	including	variants	in	SNCA,	
LRRK2,	MAPT	(microtubule-associated	protein	tau).	More	recently,	glucocerebrosidase	(GBA)	
mutations	linked	to	PD	were	also	identified	after	noting	the	presence	of	parkinsonism	in	a	cohort	of	
Gaucher’s	disease	patients	(Lwin	et	al.,	2004,	Bembi	et	al.,	2003).	SNCA	was	first	studied	via	the	
candidate	gene	approach	after	its	discovery	as	a	risk	variant	in	the	early	familial	studies	(Kruger	et	
al.,	1998).	
Multiple	candidate	gene	studies	confirmed	the	significant	correlation	between	SNCA	and	PD,	and	
studies	have	shown	that	multiple	single	nucleotide	polymorphisms	(SNPs)	spanning	the	SNCA	gene	
are	significantly	involved	with	association	(Kruger	et	al.,	1998).	The	majority	of	SNCA	studies	focused	
on	Rep1,	a	multi-allelic	polymorphism	located	upstream	from	the	SNCA	transcription	starting	point.	
German	and	Japanese	groups	confirmed	SNCA	as	a	risk	gene	in	respective	candidate	gene	studies	
and	also	showed	found	associations	for	the	same	SNP	rs356165	across	their	different	ethnic	
populations	respectively	(Mueller	et	al.,	2005,	Mizuta	et	al.,	2006),	and	Soldner	et	al	found	in	2016	
that	the	transcriptional	deregulation	of	SNCA	is	related	to	the	neurotranscription	factors	EMX2	and	
NKX6-1	(Soldner	et	al.,	2016).	SNCA	has	been	confirmed	and	established	as	a	risk	gene	with	
numerous	candidate	gene	studies	following	its	original	discovery.		
A	missense	mutation	in	LRRK2	in	an	autosomal	dominant	Japanese	family	first	indicated	that	it	is	a	
potential	risk	gene	for	PD	(Funayama	et	al.,	2005).	Candidate	gene	sequencing	also	confirmed	the	
findings	in	German-Canadian	and	American	family	(Zimprich	et	al.,	2004).	In	2009,	LRRK2	candidate	
gene	studies	in	Asian	populations	identified	one	of	the	strongest	risk	variants	p.G2385R	
(rs3477838348)	(Webber	and	West,	2009).	Later	studies	found	non-overlapping	variants	in	
Caucasian	cohorts,	although	further	GWA	studies	did	not	present	strong	statistical	support	(Healy	et	
al.,	2008b).	More	recently,	studies	using	patients	with	G2019S	mutations	have	identified	common	
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genes	for	future	candidate	studies	(Liu	et	al.,	2011).	LRRK2	is	one	of	the	most	established	PD	risk	
genes,	and	has	also	become	a	gene	of	interest	in	genetic	interaction	studies,	with	the	recent	
investigations	by	Macleod	et	al,	and	also	by	this	thesis,	into	the	functional	and	statistical	interaction	
between	PARK16	and	LRRK2.		
MAPT,	a	gene	that	encodes	the	microtubule	associated	protein	tau	was	also	discovered	using	
candidate	gene	studies	(Lill,	2016).	Several	neurodegenerative	diseases,	including	“tauopathies”,	
named	as	such	due	to	the	presence	of	tau	inclusions	in	the	diseased	brain	(Alzheimer’s	disease,	
progressive	supranuclear	palsy,	corticobasal	degeneration,	and	frontotemporal	dementia)	and	PD,	
show	increased	concentration	and	deposits	of	intraneuronal	hyperphosphorylated	tau	(Schulte	and	
Gasser,	2011).	The	mutation	only	affects	Caucasian	populations,	due	to	the	existence	of	two	
haplotypes	H1	and	H2,	where	the	primary	haplotype	H1	associated	with	PD	risk	is	found	only	in	
Caucasians	(Kwok	et	al.,	2004).	While	MAPT	has	not	been	shown	to	be	a	monogenic	cause	of	PD,	
genetic	causality	between	frontotemporal	dementia-17	(FTD-17)	and	MAPT	has	been	demonstrated	
(van	der	Zee	et	al.,	2006).		
Candidate	gene	studies	also	identified	GBA,	the	gene	that	encodes	the	enzyme	glucocerebrosidase	
as	PD	risk	variant.	First	noted	as	a	candidate	gene	due	to	the	increased	incidence	of	PD	in	families	
with	cases	of	type	1	Gaucher	disease,	clinicians	discovered	that	certain	mutations	in	GBA	increases	
risk	for	PD	(Bembi	et	al.,	2003).		Following	meta-analysis	studies	also	found	that	rare	GBA	variants	
were	also	risk	factors	for	sporadic	PD	(Aharon-Peretz	et	al.,	2004,	Sidransky	et	al.,	2009).	The	GBA	
mutation	N370S	is	the	one	most	commonly	observed	in	PD,	leading	to	a	3	fold	risk	of	developing	PD	
per	allele	(Schapira,	2015).	The	L144P	mutation	has	also	been	observed	in	multiple	cohorts,	
replicated	in	a	Chinese	and	in	French-Canadian	cohort.	Patients	with	GBA	mutations	show	the	typical	
clinical	profile	of	PD,	with	also	comparable	age	of	onsets	to	the	general	patient	population.	It	is	
hypothesized	that	degenerate	lysosomal	function	due	to	GBA	mutations	may	lead	to	SNCA	
aggegration	and	Lewy	body	formation,	thus	resulting	in	Parkinsonism	and	cognitive	degeneration	
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(Mazzulli	et	al.,	2011,	Tsuang	et	al.,	2012,	Yap	et	al.,	2013).	While	Gaucher’s	disease	is	an	autosomal-
recessive	disorder	caused	by	defective	mutations	in	both	copies	of	GBA	alleles,	the	familial	PD	and	
autosomal-dominant	PD	cases	carried	one	healthy	GBA	allele.	This	is	in	line	with	recently	studies	
that	show	that	a	partial	loss	of	function	of	the	GBA	mutation	is	causally	related	to	PD	development	
(Alcalay	et	al.,	2014).	Of	note,	the	GBA	mutations	associated	with	Parkinson’s	are	not	observed	in	
Gaucher	disease	patients,	one	hypothesized	explanation	is	that	the	mutations	are	homozygous	
embryionically	lethal,	and	thus	only	observed	in	PD	cases	with	one	functioning	gene	(Petrucci	et	al.,	
2014).		
Candidate	gene	studies	successfully	identified	the	first	set	of	PD	risk	variants.	However,	the	studies	
also	had	a	high	rate	of	false	positives	when	the	genes	were	further	investigated	inside	of	GWAS	
studies.	Many	findings	from	the	over	800	studies	were	later	found	to	be	false	positives	from	GWAS	
studies.	Candidate	gene	studies	were	limited	by	lack	of	power,	bias	from	the	patient	cohort,	and	
inappropriate	statistical	significance	thresholds.	Therefore,	while	candidate	gene	studies	were	able	
to	successfully	identify	four	major	genetic	risk	genes,	the	usage	of	GWAS	studies	opened	the	doors	
to	a	deeper	and	more	accurate	understanding	of	the	genetic	landscape	of	PD.	
GWAS	
The	genetic	understanding	of	PD	developed	in	step	with	the	advancement	of	genotyping	technology	
and	analysis	methods.	The	foundational	projects	of	the	human	genome	mapping	provided	the	
genetic	maps	necessary	to	design	powerful,	high	resolution	microarrays	(Kalinderi	et	al.,	2016).	As	of	
today,	the	most	recent	and	largest	GWAS	PD	study	confirmed	26	PD	risk	loci,	with	moderate	odds	
ratios	ranging	from	1.10	to	1.82	(Deng	et	al.,	2017).	GWA	studies	have	been	extremely	useful	in	
confirming	and	establishing	previously	identified	SNPs	of	interest	from	candidate	gene	studies.		
The	previously	discovered	SNCA,	LRRK2,	MAPT,	and	GBA	genes	have	all	also	been	confirmed	across	
the	GWA	studies	(Lill	et	al.,	2012).	For	SNCA,	two	independent	SNPs	were	identified	recently,	one	in	
the	promoter	region	of	the	gene	(rs7681154)	and	a	more	significant	SNP	approximately	~19	kb	
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downstream	from	SNCA	(rs356182)	(Pihlstrom	et	al.,	2015,	Mueller	et	al.,	2005).	The	most	recent	
GWAS	found	that	the	increased	odds	ratio	for	SNCA	to	be	around	1.30	(Nalls	et	al.,	2014),	and	SNCA	
as	a	risk	factor	has	been	consistently	validated	by	GWAS	studies	(Lill,	2016).	
GWAS	also	identified	two	rarer	additional	variants	for	GBA	(minor	allele	frequency	(MAF)	is	~0.01)	
(Sidransky	et	al.,	2009).	One	other	important	finding	recently	associated	the	human	leukocyte	
antigen	(HLA)	region	with	PD	risk,	thus	suggesting	for	the	first	time	through	genetic	evidence	that	
the	immune	system	plays	a	pathogenic	role	in	PD	disease	development	and	progression	(McGeer	
and	McGeer,	2011,	Little	et	al.,	2016).	Lastly,	GWAS	recently	also	found	a	correlation	between	PD	
risk	and	a	variant	in	intron	1	of	GCH1,	a	known	causative	gene	for	levodopa-responsive	parkinsonism	
(Mencacci	et	al.,	2014).	It	also	been	demonstrated	to	have	an	effect	across	different	ethnicities.	
More	recently,	a	group	of	Chinese	researchers	found	rare	GTP	cyclohydrolase	(GCH1)	heterozygous	
variants	with	a	risk	association	with	PD	(Xu	et	al.,	2017).	They	identified	7	rare	heterozygous	variants	
(R57Q,	S77C,	S80N,	M137V,	R198Q,	G203E,	and	G232D)	in	the	GCH1	gene.	The	GCH1	gene	is	
implicated	in	interactions	with	proteins	within	the	same	biosystem	as	PD;	but	more	research	is	
needed	to	understand	the	functionality	and	genotype-phenotype	pathways.		
The	non-candidate-driven	phenotypic	approach	of	GWAS	allows	for	the	discovery	of	completely	
novel	variants,	as	opposed	to	previous	candidate-gene	studies	(Obeso	et	al.,	2017).	While	GWAS	
studies	have	been	instrumental	in	the	confirmation	and	identification	of	new	variants	and	SNPs	in	
known	regions	of	interest,	there	are	still	limitations	to	the	study	designs.		GWAS	require	genotype	
imputation	to	estimate	genotypes	or	genotype	probabilities	at	markers	that	are	not	directly	
processed	by	a	GWAS.	Thus,	by	using	a	reference	panel	such	as	the	1000	Genomes	project	or	the	
International	HapMap	Project	or	more	densely	sequencing	only	a	subset	of	study	participants	as	
examples	of	complete	genotypes,	genotype	imputations	are	utilized	to	include	coverage	of	
genotypes	at	positions	not	assayed	in	study	samples	and	increase	the	proportion	of	common	
markers	between	different	datasets	(Martin	et	al.,	2014).	However,	imputation	also	limits	GWAS	
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studies	from	identifying	rare,	high-risk	variants	since	it	relies	on	finding	shared	haplotype	segments	
between	study	participants.	Another	point	of	difficulty	regarding	GWAS	is	that	the	signals	found	
tend	to	cover	a	relatively	large	region	that	includes	many	correlated	SNPs,	and	thus	it	is	difficult	to	
tease	out	the	pathogenic	SNP	from	the	region	of	interest	identified	by	the	studies.		
GWAS	has	also	been	commonly	used	to	identify	and	confirm	susceptibility	loci	in	AD	(Bertram,	
2009).	The	GWAS	results	have	not	been	very	consistent	in	validating	previously	discovered	genes,	
with	the	exception	of	the	ε4-allele	of	the	apolipoprotein	E	gene	(APOE)	(Bertram	and	Tanzi,	2009).	
Until	now,	GWAS	studies	in	AD	have	identified	23	risk	loci	(Lambert	et	al.,	2013).	The	low	degree	of	
penetrance	and	diffuse	findings	suggest	that	sporadic	late-onset	AD	has	a	complicated	genetic	
architecture	with	many	low-risk	common	alleles.		
Next	generation	sequencing,	including	WES	and	whole-genome	sequencing	(WGS),	are	able	to	better	
grapple	with	rare	variants	and	address	many	of	the	short	comings	of	GWAS	in	identifying	rare,	high-
risk	variants	(Bras	et	al.,	2012).	In	particular.	Whole	genome	studies	provide	increased	coverage	and	
reduces	bias	due	to	fewer	amplification	steps,	and	is	given	the	current	methods,	the	optimal	method	
of	identification	of	rare,	high-risk	variants	(Jansen	et	al.,	2017).	It	is	our	best	method	moving	forward	
for	discovering	new	genetic	defects,	although	GWAS	studies	and	candidate	based	exome-chip	
studies	are	still	useful	for	the	right	questions,	and	much	less	resource-intensive.		
	
Synucleinopathies	and	tauopathies	
	
PD	belongs	to	a	larger	diverse	group	of	neurodegenerative	proteinopathies	defined	by	the	presence	
of	alpha-synuclein	lesion	formation.	The	major	pathological	characteristic	of	alpha-synucleinopathies	
(AS)	is	the	presence	of	AS-positive	lesions	in	the	neuronal	and	glial	cells.	The	protein	was	first	
discovered	to	be	related	to	PD	in	1998,	when	Spillantini	et	al.	demonstrated	that	Lewy	bodies,	one	
of	the	defining	histological	traits	of	PD,	displayed	high	immunoreactivity	for	AS	(Goedert	et	al.,	
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2017).	Additional	studies	demonstrated	that	Lewy	bodies	and	Lewy	body	filaments	obtained	from	
PD	patients	also	tested	positive	for	alpha-synuclein	through	antibody	staining.	Lewy	body	formation	
without	symptoms,	believed	to	be	prodromal	for	diseases	with	Lewy	bodies,	is	observed	in	5-10%	of	
the	generation	population	over	60	years	of	age	(Gibb	and	Lees,	1988,	Forno,	1969).	Thus,	the	
prevalence	of	neurodegenerative	diseases	correlated	to	alpha-synuclein	is	quite	high	in	the	elderly	
population	and	in	neurodegenerative	diseases,	representing	a	significant	disease	burden.		
MSA	
MSA	is	another	neurodegenerative	disease	characterized	by	alpha-synuclein	deposits.	However,	the	
deposits	in	MSA	are	not	Lewy	bodies.	Instead,	the	defining	pathological	features	are	alpha-
synuclein-immunoreactive	filamentous	lesion	deposits	in	primarily	glial	cells	(Fellner	and	Stefanova,	
2013).	It	is	characterized	by	a	diverse	set	of	extrapyramidal,	pyramidal,	autonomic,	and	cerebellar	
symptoms,	with	parkinsonism	seen	in	almost	all	patients	as	disease	progresses	(Jellinger,	2003).	
Genetic	associations	have	been	reported	between	MSA	and	alpha-synuclein,	in	particular	with	the	
cerebellar	subtype	of	MSA	(Al-Chalabi	et	al.,	2009).	GWAS	failed	to	identify	any	genome	wide	
significant	risk	loci	but	did	find	several	regions	of	interest	including	SNPs	in	MAPT,	FBXO47,	EDN1,	
and	ELOVL7	(Sailer	et	al.,	2016).	
Tauopathy	
While	alpha-synuclein	is	the	primary	protein	associated	with	PD,	the	tau	protein	also	features	
prominently	in	neurodegenerative	diseases	such	as	AD,	CBD,	Pick’s	disease	(PiD),	and	FTD	(Goedert,	
2004).	Tau	is	a	protein	that	assists	in	the	stabilization	and	assembly	of	microtubules.	Commonly	
found	on	the	axons	of	nerve	cells,	it	also	appears	in	diseased	brains	on	cell	bodies	and	dendrites.	AD,	
the	most	prevalent	neurodegenerative	disease,	is	defined	by	the	presence	of	beta-amyloid	neuritic	
plaques	and	intraneuronal	neurofibrillary	lesions	comprised	of	tau	proteins	(Hernandez	and	Avila,	
2007).	Tau	lesions	without	the	presence	of	beta-amyloid	plaques	are	also	the	defining	characteristic	
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of	other	neurodegenerative	diseases	such	as	progressive	surpranuclear	palsy	(PSP),	Pick’s	disease	
(PiD),	and	corticobasal	degeneration	(CBD)	(Lee	et	al.,	2001).	
CBD	is	a	neurodegenerative	disorder,	characterized	by	adult-onset,	progressive	disease	
pathogenesis,	and	marked	neuronal	achromasia,	that	affects	the	cerebral	cortex,	substantia	nigra,	
and	deep	cerebellar	nuclei	(Goedert,	2004).		Affected	regions	feature	high	concentrations	of	glia	and	
neuronal	intracytoplasmic	filamentous	tau	deposits.	One	of	the	defining	features	of	CBD	is	the	
extensive	presence	within	the	cortical	and	subcortical	areas	of	tau-immunoreactive	neuropil	
filaments.	PSP	is	a	related	disease	of	CBD;	both	diseases	display	similar	biochemical	tau	profiles.	PSP	
is	characterized	by	the	symptoms	of	postural	instability	and	supranuclear	gaze	palsy	(Goedert,	
2004).	Its	neurological	disease	profile	includes	neuronal	atrophy,	gliosis,	and	degradation	of	the	
basal	ganglia,	subthalamus,	and	brainstem.	Genetic	studies	have	demonstrated	substantial	
correlation	between	the	two	diseases	and	the	same	A0	allele	of	the	tau	gene	(Soto-Ortolaza	and	
Ross,	2016).	In	particular,	GWAS	studies	have	identified	shared	variants	between	PSP	and	CBD	in	the	
myelin-associated	oligodendrocyte	basic	protein	(MOBP)	and	MAPT	loci	(Kouri	et	al.,	2015).	Given	
the	similar	biochemical	profile	and	genetic	correlation,	it	is	possible	that	the	two	diseases	are	
actually	different	physical	manifestations	of	the	same	neurological	disease	pathogenesis	(Soto-
Ortolaza	and	Ross,	2016).		
PiD	is	a	variant	of	FTD,	and	is	defined	by	the	appearance	of	tau-immunoreactive	Pick	bodies	
(Goedert	et	al.,	2001).	The	neurological	disease	pathogenesis	is	characterized	by	degradation	of	the	
frontotemporal	lobes	and	the	limbic	system,	with	neuronal	loss,	gliosis,	spongiosis,	and	Pick	bodies.	
The	tau	found	in	PiD	exhibits	a	different	biochemical	profile	from	the	tau	protein	found	in	AD,	CBD,	
and	PSP	(Lee	et	al.,	2001).		
The	last	group	of	tauopathies	discussed	is	FTDP-17	with	parkinsonism.	Comprised	of	autosomal-
dominant	neurodegenerative	diseases	that	all	present	with	extensive	tau	filaments	in	nerve	cells	and	
in	some	cases	also	glial	cells,	the	disease	family	is	linked	to	a	series	of	mutations	in	the	same	region	
	
	
28	
of	chromosome	17	(Foster	et	al.,	1997).	Depending	on	the	site	of	the	disease	burden	in	the	brain,	
patients	present	with	different	syndromes	and	disease	phenotypes	of	FTDP-17.	However,	all	FTDP-
17	syndromes	present	with	neuronal	atrophy	in	the	affected	area	and	extensive	
hyperphosphorylated	tau	filament	pathology	in	neuronal	and	also	possibly	glial	cells	(Foster	et	al.,	
1997).	This	develops	phenotypically	with	progressive	degeneration	of	cognitive,	motor,	and	
executive	neuronal	functions.	A	GWA	study	for	FTD	identified	risk	variants	in	the	HLA	locus	across	
entire	and	a	new	locus	at	RAB36/CTSC	(related	to	lysosomal	biology)	in	the	FTD	behavioral	subtype	
(Ferrari	et	al.,	2014).	
Epidemiology	of	PD	
MPTP	
Langston	and	colleagues	established	in	1983	that	1-methyl-4-phenyl-1,2,3,6-tetra	hydropyridine	
(MPTP)	breaks	down	in	the	body	into	a	pre-parkinsonian	molecule,	1-methyl-4-phenyl	pyridnium	
(MPP+),	and	resulted	in	chronic	parkinsonism	and	dopaminergic	neural	degeneration(Langston	and	
Ballard,	1984).	Furthermore,	drug	addicts	accidentally	injected	with	MPTP,	a	by-product	of	
meperidine	synthesis,	showed	clinical	symptoms	and	pathology	in-line	with	PD(Davis	et	al.,	1979).		
Environmental	epidemiology	has	also	linked	the	pesticide	paraquat	and	Maneb,	containing	a	
chemical	structured	similar	to	MPTP,	with	PD	(Desplats	et	al.,	2012).	The	majority	of	the	
epidemiological	pesticide	studies	treat	exposure	as	a	dichotomous	variable;	with	most	studies	
reporting	ORs	between	1.3-3.7	in	increased	risk	of	PD	after	exposure.	Interaction	effects	between	
Paraquat	and	Maneb	and	the	LRRK2	G2019S	mutation	has	also	been	demonstrated	(Desplats	et	al.,	
2012).	Studies	have	found	a	3-fold	increase	in	risk	of	PD	development	in	workers	that	carry	one	of	
the	susceptibility	alleles	in	the	dopamine	transport	gene	SLC6A3	(rs2652510,	rs2550956,	VNTR)	and	
a	4-fold	increase	in	workers	with	more	than	risk	allele	(Ritz	et	al.,	2009).		
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Smoking	
PD	is	also	inversely	related	to	smoking	through	the	nicotinic	acetylcholine	receptor,	with	smoking	
reducing	risk	of	disease	by	up	to	70%	(Ritz	et	al.,	2009).	The	nicotine	receptor	activates	signaling	
molecules	downstream,	thus	possibly	slowing	the	progression	and	severity	of	PD	by	protecting	the	
cells	and	decreasing	cellular	death,	increasing	neuronal	survival,	and	also	possibly	attenuating	
immune	activity	(Quik	et	al.,	2012).	Thus,	the	resulting	adaptations	in	the	immune	system	
responsiveness	appears	to	ameliorate	the	damage	from	PD,	reducing	the	severity	of	symptoms	(Quik	
et	al.,	2012).	Additionally,	nicotine	itself	both	improves	cognition	and	attention	and	also	has	anti-
depressant	characteristics,	thus	countering	the	mental	health	and	cognitive	symptoms	of	PD	(Quik	et	
al.,	2012).	The	protective	effect	has	been	confirmed	by	meta-analyses,	and	modeling	methods	have	
also	observed	a	correlation	between	reduced	risk	and	time-since-cessation,	specifically	that	the	
protective	effect	diminishes	the	longer	the	time	since	cessation	(Hernan	et	al.,	2002).		There	have	
also	been	indications	of	gene-environment	interaction	between	PD	and	smoking,	with	evidence	that	
one	or	more	GSTP1	polymorphisms	modulates	the	risk	of	PD	in	conjunction	with	smoking,	where	
carriers	of	the	GSTP1*C	haplotypes	are	more	prevalent	in	PD	patients	that	smoke	(Checkoway	et	al.,	
1998).	Additionally,	the	MAO-B	gene	displayed	only	male	gender-specific	interactions	between	
smoking	and	the	A/G	polymorphism	(OR=0.27,	95%	CI	(0.13-0.58)	for	smokers	versus	non-smokers,	
and	OR=1.26	(0.60-2.63)	for	men	of	genotype	A	(X2=8.14,	p=0.004))	(Polito	et	al.,	2016).	The	
epidemiological	relationship	with	cigarette	smoke	and	PD	has	been	established.	However,	more	
research	needs	to	be	done	to	understand	the	functional	relationship	between	cigarette	smoke	and	
PD.		
Coffee	
Coffee	consumption	has	also	been	shown	to	significantly	decrease	PD	risk,	with	consistent	findings	
across	multiple	studies.	Caffeine	is	a	commonly	consumed	methylxanthine,	thus	belonging	to	a	class	
of	pharmacological	molecules	that	have	an	antagonistic	effect	on	the	adenosine	receptors	(Yamada-
Fowler	and	Soderkvist,	2015).	Adenosine	receptors	modulate	the	nigrostriatal	dopamine	system,	and	
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it	has	been	shown	that	adenosine	A2A	antagonists	reduce	the	amount	of	awake	OFF	time	in	PD	
patients	with	motor	control	issues	(Nicoletti	et	al.,	2015).	Furthermore,	it	appears	that	caffeine	
attenuates	the	toxicity	of	alpha-synuclein	aggregates,	thus	possibly	reducing	the	impact	of	alpha-
synuclein	related	gene	mutations	(Yamada-Fowler	and	Soderkvist,	2015).	A	dose	effect	where	
increasing	cups	leads	to	decreasing	risk	has	also	been	observed.	Odds	ratio	on	the	order	of	0.44	
(95%	CI	0.23-0.83,	P=0.01)	were	observed,	with	a	further	reduction	in	risk	when	the	number	of	cups	
per	day	increases	(1-3	versus	more	than	3)	(Polito	et	al.,	2016).	A	recent	GWAS	identified	GRIN2A,	an	
N-methyl-D-aspartate	receptor	(NMDA)	glutamate-receptor	subunit	that	is	a	part	of	the	excitatory	
pathways,	as	another	disease	modifier	that	reduces	risk	in	conjunction	with	caffeine	intake(Yamada-
Fowler	and	Soderkvist,	2015).	In	an	ethnically	homogenous	Swedish	cohort,	there	were	both	strong	
joint	effects	of	gene	and	caffeine	on	PD	risk,	and	also	a	gene-caffeine	interaction	affect,	which	was	
very	mildly	protective	but	significant	(joint	effect	OR=0.38	95%	CI	(0.20-0.70),	p=0.002	for	TC	heavy	
caffeine	versus	CC	light	caffeine	and	gene-caffeine	interaction	(OR=0.998	95%	CI	(0.991-0.999)	p-
value<0.001)	(Polito	et	al.,	2016,	Hernan	et	al.,	2002).The	effect	of	caffeine	also	manifests	itself	in	
tea	consumption.	However,	contradictory	findings	between	the	protective	effect	of	either	black	or	
green	tea	indicate	that	further	studies	are	needed	to	substantiate	and	clarify	the	role	that	tea	plays	
on	the	risk	of	developing	PD.		
Uric	Acid	
Uric	acid	(Urate)	is	found	at	high	concentrations	in	the	body.	The	metabolic	end	product	of	purines,	
studies	have	shown	it	to	have	protective	effects	from	degeneration	of	dopaminergic	neurons.	One	
study	investigated	the	effect	of	serum	urate	levels	on	PD	risk,	finding	a	protective	effect	from	higher	
serum	urate	levels	on	the	likelihood	of	PD	development.	Mendelian	Randomization	(MR)	has	also	
been	utilized	in	the	epidemiology	of	PD	and	serum	urate	levels	(Simon	et	al.,	2014).	Using	80	
patients	with	3	SLC2A9	genotyped	SNPs	related	to	lower	urate	concentrations,	Simon	et	al	found	an	
increased	hazard	ratio	for	progression	to	dopaminergic	treatment	for	patients	with	more	minor	
alleles	of	the	three	loci,	thus	tying	more	rapid	progression	of	PD	to	lower	serum	urate	levels.		
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Iron	Levels	
Pathological	studies	from	post-mortem	PD	patients	have	found	increased	levels	of	iron	in	the	SN	and	
lateral	globus	pallidus	(Dusek	et	al.,	2012).	MR	is	a	powerful	tool	that	that	uses	the	genetic	variant	
tied	to	a	specific	phenotype	as	an	instrumental	variable	in	epidemiological	studies.	Pichler	et	al	use	
three	genetic	variables	that	affect	iron	levels,	HFE	rs1800562,	HFE	rs1799945,	and	TMPRSS6	
rs855791	(Pichler	et	al.,	2013).	The	three	alleles	are	known	to	increase	iron	levels,	confirmed	with	
large	scale	meta-analyses	of	GWAS	in	general	population	(Pichler	et	al.,	2013).	Using	MR,	the	study	
found	a	protective	effect	on	the	risk	of	PD	development	with	one	standard	deviation	unit	increase	in	
serum	iron	levels,	with	overall	OR	found	to	be	0.88	(95%	CI:	(0.82,	0.95),	p=0.001).	With	a	study	size	
of	over	21,000	individuals	of	European	and	Australia	descent,	the	findings	using	MR	suggest	a	causal	
relationship	between	iron	levels	and	PD	development	(Pichler	et	al.,	2013).	The	functional	
relationship	remains	unclear,	but	theories	suggest	that	the	reduction	in	free	ferritin	in	the	brain	
could	decrease	neuronal	iron	usage	by	lowering	the	amount	of	iron	available	for	neuronal	enzymes,	
thus	possibly	linking	the	commonly	observed	lower	levels	in	the	substantia	nigra	of	iron	in	neurons	
in	PD	patients	to	a	lower	concentration	of	free	iron	(Zecca	et	al.,	2004a,	Zecca	et	al.,	2004b).	Mice	
studies	similarly	demonstrated	that	an	iron-restricted	diet	related	to	the	decline	in	the	levels	of	
striatal	dopamine	(Jellen	et	al.,	2013).	Thus,	using	MR,	the	study	suggests	a	causal	relationship	
between	iron	exposure	and	outcome,	with	more	robust	inference	than	one	can	make	from	a	purely	
observational	study.		
Future	directions	
The	epidemiology	of	PD	has	matured	since	its	inception,	however,	we	still	only	can	account	for	a	
small	fraction	of	the	causality	of	PD	cases.	From	the	environmental	perspective,	while	we	have	
found	strongly	effective	compounds	that	either	increase	or	decrease	disease	risk,	causality	still	
remains	an	open	question	in	many	cases.	Environmental	factors	do	not	have	complete	penetrance.	
From	the	genetics	angle,	only	approximately	10%	of	sporadic	PD	cases	are	explained	by	monogenic	
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inheritance	patterns	of	known	genes.	The	incomplete	penetrance	of	the	mutations	demonstrates	
that	it	is	highly	unlikely	that	the	genes	act	alone	to	instigate	disease.	Unlike	monogenic	diseases	such	
as	Huntington’s,	one	sees	that	the	genetic	basis	of	PD	is	complex	and	multi-faceted.	Thus,	further	
research	in	the	field	should	not	only	concentrate	on	the	discovery	of	novel	SNPs,	but	also	on	the	
possibilities	of	genetic	pleiotropy,	cross-disease	effects,	gene-gene	interactions,	and	gene-
environment	interactions	and	their	modulation	of	the	effect	of	the	single	SNPs.		
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Chapter	2	Results	
The	results	section	consists	of	the	two	published	manuscripts,	the	relevant	supplementary	materials	
pertaining	to	the	publication,	and	the	3rd	submitted	manuscript.	All	results	presented	are	first	author	
publications.		
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Part	1:	Large	Scale	Assessment	of	Polyglutamine	Repeats	Expansions	in	Parkinson’s	disease	
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Figure	e-1:	Density	Plots	comparing	Allelic	Distribution	of	Repeat	Lengths	for	SCA2,	SCA3,	SCA6,	
SCA17.	Complete	Cohorts.	
	
	
	
	
	
	
	
	
	
Table	e-1a:	Distribution	of	allele	frequency	of	SCA	loci		
SCA	 Cases	(%)	 Controls	(%)	 Chi-Square	 All,	pvalue	 Asian,	pvalue	 Caucasian,	pvalue	
SCA2	 8029	(41%)	 11587	(59%)	 2.1	 0.35	 0.15	 0.31	
SCA3	 8005	(41%)		 11662	(59%)	 0.1	 0.78	 0.73	 0.30	
SCA6	 7732	(40%)	 11519	(50%)	 6.2	 0.01	 0.39	 0.13	
SCA17	 7926	(41%)	 11578	(59%)	 0.1	 0.78	 0.74	 0.97	
Comparison	performed	using	CLUMP	between	cases	and	controls	in	overall	cohort	
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Table	e-2b:	Overall	effect	estimates	for	SCA	loci	in	Asian	and	Caucasian	population		
Cohort	 Locus	 Gene	Name	 Q	test	pvalue	 OR	(95%	CI)	 I^2	 RE	pvalue	 FE	pvalue	
Asian	 SCA2	 ATXN2	 0.08	 0.52	(0.19,	1.48)	 61	(0,	99)	 0.22	 0.07	
		 SCA3	 ATXN3	 0.45	 0.90	(0.61,	1.31)	 0	(0,	91)	 0.57	 0.57	
		 SCA6	 CACNA1A	 0.42	 1.04	(0.87,	1.23)	 21	(0,	83)	 0.61	 0.38	
		 SCA17	 TBP	 0.86	 0.90	(0.39,	2.07)	 0	(0,	80)	 0.81	 0.81	
Caucasian	 SCA2	 ATXN2	 0.12	 1.09	(0.87,	1.38)	 30	(0,	79)	 0.46	 0.40	
		 SCA3	 ATXN3	 0.58	 1.00	(0.61,	1.64)	 0	(0,	74)	 0.99	 0.99	
		 SCA6	 CACNA1A	 0.92	 0.98	(0.90,	1.05)	 0	(0,	29)	 0.52	 0.52	
		 SCA17	 TBP	 0.86	 1.04	(0.49,	2.21)	 0	(0,	63)	 0.93	 0.93	
RE=	Random	Effects,	FE=	Fixed	Effects,	CI=	Confidence	Interval,	OR=	Odds	Ratio	
	
Table	e-2c:	Overall	summary	estimates	for	SCA2	stratified	by	ethnicity	using	repeat	length	cut-off	of	
25	
SCA2	 Q	test	pvalue	 OR	(95%	CI)	 I^2	 RE	pvalue	 FE	pvalue	
Complete	 0.034	 1.01	(0.80,	1.28	)	 37	(0,	83	)	 0.93	 0.76	
Asian	 0.084	 0.52	(0.19,	1.48	)	 61		(0,	100	)	 0.22	 0.08	
Caucasian	 0.12	 1.09	(0.87,	1.38	)	 30	(0,	79	)	 0.46	 0.40	
RE=	Random	Effects,	FE=	Fixed	Effects,	CI=	Confidence	Interval,	OR=	Odds	Ratio	
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Part	2:	Evaluation	of	the	interaction	between	LRRK2	and	PARK16	loci	in	determining	risk	of	
Parkinson’s	disease:	analysis	of	a	large	multicenter	study	
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Supplementary	Materials	
	
1. Introduction	
While	a	comprehensive	evaluation	of	interactions	of	PD	susceptibility	has	yet	to	be	performed,	
several	studies	have	investigated	the	interactions	between	various	genes	of	interest1-4.	Although	the	
results	of	most	gene-gene	interactions	studies	in	PD	to	date	have	pointed	toward	independent	
effects	for	PD	susceptibility	variants,	an	exception	to	this	has	been	assessments	of	functional-genetic	
interaction	between	LRRK2	and	PARK16	locus5-7,	with	a	previous	study	demonstrating	through	
protein-protein	interaction	arrays	that	RAB7L1	is	a	binding	partner	for	LRRK25	More	recently,	
Kuwahara	et	al	also	demonstrated	that	orthologues	of	LRRK2	and	RAB7L1	in	C.	elegans	neurons	
work	together	concomitantly	in	an	ordered	pathway	to	determine	axonal	length6.	One	recent	study	
also	found	function	evidence	that	overexpression	of	RAB7L1,	a	candidate	gene	for	PARK16	locus,	
reversed	the	effects	of	the	LRRK2	mutation	and	rescued	the	phenotype8.		Furthermore,	effect	of	the	
LRRK2	risk	variant	(rs1176052)	was	negated	in	individuals	with	a	copy	of	the	protective	allele	for	the	
PARK16	variant	(rs823114)8.		This	initial	identification	of	an	interaction	between	LRRK2	and	PARK16	
regarding	susceptibility	to	PD	leads	to	several	important	follow-up	questions,	such	as	whether	the	
interaction	is	still	evident	when	even	larger	series	are	examined,	whether	it	is	consistent	for	subjects	
of	differing	ethnicities	and	from	different	geographic	regions,	and	whether	it	remains	apparent	for	
other	variants	in	the	two	loci.		Therefore,	the	aim	of	this	study	was	to	evaluate	the	interaction	
between	several	different	LRRK2	and	PARK16	variants	in	determining	PD	risk	using	a	Caucasian	
series	consisting	of	more	than	10,000	subjects	from	14	different	centers,	and	an	Asian	series	
comprised	of	more	than	5,000	subjects	from	5	different	centers.	
	
2. Methods	
2.1	Participants	
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http://www.geo-pd.org/about/Diagnosis	of	PD	was	made	according	to	standard	criteria9,10.	Controls	
were	individuals	free	of	any	extra-pyramidal	disorder.	All	subjects	were	unrelated,	and	carriers	of	
pathogenic	LRRK2	mutations	were	excluded.	Demographic	information	of	PD	patients	and	controls	
for	each	GEoPD	site	is	provided	in	Supplementary	Table	1.	We	selected	LRRK2	rs1491942	and	LRRK2	
rs7133914	in	concordance	with	previously	demonstrated	associations11,12.	Of	note,	LRRK2	rs7133914	
(LRRK2	p.R1398H)	is	part	of	a	3-SNP	haplotype	(p.N551K-R1398H-K1423K)	that	has	been	shown	to	
be	protective	for	PD,	and	was	selected	for	inclusion	for	this	study	as	it	has	been	shown	to	be	the	
most	likely	functional	variant	on	the	haplotype13,14.		The	Japanese	site	from	our	Asian	series	utilized	
genotype	data	from	a	previous	GWAS15.	If	the	LRRK2	and	PARK16	SNPs	of	interest	in	this	study	were	
not	directly	genotyped	in	Japanese	GWAS	cohort,	we	used	proxy	SNPs	with	r2	values	>0.8	to	fully	
capture	genetic	information.	Using	these	proxy	criteria,	we	were	able	to	match	exact	SNPs	from	the	
Japanese	GWAS	cohort	for	four	SNPs	(rs708725,	rs823139,	rs823156,	rs11240572)	within	the	
PARK16	locus,	and	a	single	proxy	SNP,	rs2201144,	was	identified	for	LRRK2	rs1491942.	LRRK2	
rs7133914	was	not	genotyped	in	the	Asian	series	and	was	genotyped	for	only	a	subset	of	the	
Caucasian	series	(3622	patients,	3042	controls).		Furthermore,	Haploview	was	used	to	measure	the	
LD	coefficient	between	SNPs	used	in	our	study	and	with	that	of	MacLeod	et	al5.	All	variants	followed	
Hardy	Weinberg	Equilibrium	(HWE)	in	controls.	All	genotype	call	rates	were	>97%.	We	found	limited	
linkage	disequilibrium	between	the	variants	within	the	same	gene	or	locus	(r2<0.50	in	all	cases).	
	
The	Department	of	Human	Genetics	of	the	Helmholtz	Center	served	as	the	genotyping	core	and	
performed	all	genotyping	(Munich).	Each	site	sent	100–200	ng	of	DNA	to	the	laboratory	core.	Case-
control	status	was	blinded	at	the	genotyping	code	for	each	site.	We	performed	the	genotyping	on	a	
matrix-assisted	laser	desorption/ionization	time-of-flight	(MALDI-TOF)	mass	spectrometry	on	a	
MassArray	system	(Sequenom,	San	Diego,	CA).	A	mass	spectrometer	analyzed	the	cleaned	extension	
products	(Bruker	Daltronik,	USA),	and	the	MassArray	Typer	4.0.2.5	software	was	used	for	peak	
identification	(Sequenom).	The	AssayDesigner	software	4.0	(Sequenom)	was	used	for	assay	design,	
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with	the	default	parameters	for	the	iPLEX	Gold	chemistry	and	the	Human	GenoTyping	Tools	ProxSNP	
and	PreXTEND	(Sequenom).	One	multiplex	assay	was	used	to	genotype	all	of	the	variants.	To	check	
genotype	clustering,	an	experienced	investigator	blinded	to	patient	affection	status	visually	
reviewed	the	sample	results.		
	
2.4	Statistical	analysis	
Sensitivity	of	the	results	of	gene-gene	interaction	analysis	to	the	use	of	random	effects	models	was	
also	considered16.	Not	all	of	the	sites	had	complete	information	on	age	and	gender,	and	thus	we	
performed	secondary	analyses	with	adjustment	for	age	and	gender.	Cochran’s	Q	test	of	
homogeneity	was	used	to	evaluate	between-site	heterogeneity,	along	with	the	I2	metric,	which	is	
interpreted	as	the	proportion	of	variation	in	between-site	interaction	ORs	that	is	due	to	
heterogeneity	beyond	chance17,18.	
To	aid	in	the	interpretation	of	tests	of	interaction,	we	also	combined	the	two	variants	involved	in	the	
given	interaction	into	one	variable,	allowing	for	a	different	category	for	each	different	genotype	
combination.	The	association	between	this	genotype	combination	variable	and	PD	was	then	
evaluated	using	a	fixed	effects	logistic	regression	model	adjusted	for	GEO-PD	site,	where	the	most	
common	genotype	combination	was	the	reference	category,	and	ORs	and	95%	CIs	were	estimated	in	
relation	to	this	reference	category.	P-values	were	also	calculated	for	comparison	of	the	reference	
category,	though	the	ORs	and	95%	CIs	are	of	most	interest	in	interpreting	the	interaction	(or	lack	
thereof)	between	the	given	two	variants	and	p-values	are	presented	mostly	for	completeness.	We	
refer	to	these	analyses	where	the	joint	effect	of	the	given	two	SNPs	on	PD	risk	is	being	examined	as	
“tests	of	association”.	To	be	clear,	these	tests	of	association	are	presented	only	to	assist	in	the	
interpretation	of	the	aforementioned	gene-gene	interactions,	and	do	not	represent	tests	of	
interaction	themselves19.			
Variants	with	a	minor	allele	frequency	(MAF)	less	than	10%	in	either	one	of	the	series	(Caucasian	or	
Asian)	were	evaluated	under	a	dominant	model	(i.e.	presence	vs.	absence	of	the	minor	allele)	in	all	
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analyses	to	maintain	consistency	of	statistical	models	and	allow	for	comparison	of	results	between	
series.	Subjects	were	coded	as	either	0	(absence	of	the	minor	allele)	or	1	(presence	of	the	minor	
allele)	for	each	variant.	Variants	with	a	MAF	of	10%	or	greater	in	both	the	Asian	and	Caucasian	series	
were	examined	under	an	additive	model	(i.e.	effect	of	each	addition	allele),	with	the	subject	coded	
as	(0,1,2),	depending	on	the	number	of	copies	of	the	minor	allele.	Under	this	rule,	LRRK2	variant	
rs7133914	and	PARK16	rs11240572	were	coded	under	the	dominant	scheme,	and	LRRK2	1491942	
and	PARK16	rs823139	[RAB7L1],	rs70875	[RAB7L1],	rs823156	[SLC41A1],	and	rs708723	[RAB7L1]	
were	coded	under	the	additive	scheme.		All	statistical	tests	were	two-sided,	with	multiple	testing	
correction	set	at	0.005	for	2-sided	p-value,	due	to	the	10	different	combinations	of	SNPs.	All	
statistical	analyses	were	performed	using	R	Statistical	Software	(version	3.0.2,	R	Foundation	for	
Statistical	Computing,	Vienna,	Austria).	
3.	Results	
A	total	of	19	sites	contributed	7627	PD	patients	and	8261	neurologically	normal	patients	
(Supplementary	Table	1).	Out	of	the	19	sites,	14	sites	contributed	data	of	Caucasian	ancestry	and	
five	sites	contributed	data	of	Asian	ancestry.	The	proportion	of	men	ranged	from	41.6%	to	67.8%	in	
PD	patients	and	35.1%	to	62.3%	in	controls	(Supplementary	Table	1).	The	mean	age	at	onset	was	
68.1	years	for	PD	patients,	and	comparable	to	the	mean	age	of	study	of	healthy	controls	was	67.5	
years	(Supplementary	Table	1).	Of	note,	given	the	homogenous	nature	of	the	Belgium	population,	
we	combined	the	data	from	the	two	Belgium	sites	(Garraux	and	von	Broeckhoven)	in	all	analyses	
due	to	the	smaller	sample	size	of	the	Garraux	site	(Supplementary	Table	1).			
Associations	of	each	of	the	eight	individual	PARK16	and	LRRK2	variants	with	risk	of	PD	are	shown	in	
Supplementary	Table	2.		Although	some	of	these	associations	have	largely	been	shown	previously,	it	
is	helpful	to	first	understand	single-variant	associations	before	examining	interactions.	LRRK2	
rs1491942	was	associated	with	an	increased	risk	of	PD	in	the	Caucasian	series	(OR:	1.16,	P=2.2E-05)	
but	not	the	Asian	series	(OR:	1.10,	P=0.03)	(Supplementary	Table	2).		For	PARK16,	a	risk	effect	was	
observed	for	rs708723	in	the	Asian	series	(OR:	1.76,	P=0.00011)	but	not	Caucasian	series	(OR:	1.03,	
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P=0.32),	while	protective	effects	were	noted	for	both	rs708725	in	the	Caucasian	series	and	for	
rs708725,	rs823139,	rs823156,	and	rs11240572	in	the	Asian	series	(Supplementary	Table	2).	
Supplementary	Tables	3-5	contain	the	results	for	the	multiplicative	interaction	analysis	between	
LRRK2	rs1491942	and	PARK16	SNPs,	for	both	the	combined	and	the	individual	Caucasian	and	Asian	
series.	Supplementary	Table	6	shows	the	results	for	the	stratified	analysis	between	LRRK2	rs1491942	
and	PARK16	rs11240572,	where	we	observe	a	trend	in	the	stratified	analysis;	however	the	
multiplicative	interaction	is	not	significant	after	multiple	testing	correction.	Supplementary	Table	7	
displays	the	results	of	the	multiplicative	interaction	between	LRRK2	rs7133914	and	the	PARK16	
SNPs,	no	interaction	effects	of	note	were	observed.		
	
4.		Discussion		
The	identification	of	genetic	mutations	in	genes	linked	to	familial	forms	of	PD	(e.g.	LRRK2,	VPS35,	
DNAJC13)	and	genetic	variability	within	the	PARK16	locus	in	GWAS	strongly	implicates	the	role	of	
retromer	and	lysosomal	pathway	in	PD	pathogenesis20,21.		Mutant	forms	of	LRRK2	have	been	shown	
to	affect	RABL71	dependent	lysosomal	clustering	and	thus	linking	endosomal	pathway	to	PD.	
Additionally,	previous	functional	studies	have	demonstrated	that	LRRK2	and	RAB7L1	work	together	
in	regulating	axonal	elongation6.	Interestingly,	deficiency	of	the	PARK16	locus	candidate	gene,	
RAB7L1,	in	mammalian	or	Drosophila	dopamine	neurons	causes	neurodegeneration;	in	contrast,	
overexpression	of	the	RAB7L1	rescued	the	LRRK2	mutant	phenotype	suggesting	that	both	RAB7L1	
and	LRRK2genes	bound	together	and	functionally	interact	with	each	other	in	regulating	neurite	
length	process	in	vitro	and	in-vivo7.	Therefore,	to	understand	the	impact	of	interaction	in	world-wide	
populations,	we	performed	a	large-multi-center	study	to	assess	the	genetic	evidence	of	interaction	
between	LRRK2	and	PARK16	locus.		
	
The	results	of	our	study	do	not	provide	evidence	of	a	genetic	interaction	between	PARK16	and	
LRRK2	variants	with	regard	to	risk	of	PD.	Heterogeneity	in	between-site	interaction	OR	estimates	
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was	minimal,	thus	the	lack	of	interaction	was	consistently	observed.	It	is	unlikely	that	our	results	are	
influenced	by	analyzing	different	SNPs	as	compared	to	MacLeod	study.	Indeed,	we	observed	high	D’	
prime	(range	0.5	-1.0)	between	our	LRRK2	SNPs	and	SNPs	analyzed	in	a	previously	published	study,	
and	similarly	for		our	PARK16	SNPs	(range	0.15-1)	indicating	that	our	SNPs	fully	captured	the	genetic	
information	covered	by	MacLeod	et	al.		
	
Of	note,	the	directionality	of	effect	estimates,	albeit	with	a	much	weaker	effect	size	observed	in	the	
present	study,	involving	the	specific	LRRK2	rs1491942/PARK16	rs11240572	interaction	are	in	
agreement		with	previously	published	findings8.	Specifically,	while	both	studies	observed	ORs	very	
close	to	1	for	the	LRRK2	variant	that	was	examined	in	the	given	study	in	carriers	of	the	rare	PARK16	
allele,	ORs	associated	with	the	LRRK2	variant	were	greater	than	1	in	our	study	(ORs	of	1.13	and	1.17	
in	the	Asian	and	Caucasian	series)	and	in	the	MacLeod	study	(ORs	ranging	from	1.31	to	2.49	in	the	4	
different	series	examined)	for	non-carriers	of	the	PARK16	minor	allele.		
	
Several	limitations	of	our	study	should	be	noted.	Genetic	interaction	studies	are	limited	by	sample	
size	and	power	due	to	the	fact	that	variable	of	focus	in	an	interaction	study	is	the	presence	of	the	
genotype	of	interest	for	both	variants,	and	this	occurs	much	less	frequently	than	the	individual	
variant	genotypes.	As	a	result,	even	with	our	large	sample	size,	power	is	still	limited	to	detect	
moderate	to	small	gene-gene	interaction	effects.	Therefore,	the	possibility	of	a	false-negative	finding	
is	important	to	bear	in	mind,	and	95%	confidence	limits	for	interaction	OR	estimates	should	be	
considered	when	interpreting	results.	Finally,	we	cannot	exclude	the	possibility	that	population	
stratification	could	have	had	an	impact	on	our	results,	however	our	analysis	adjusting	for	GEO-PD	
site	would	have	accounted	for	that	to	a	large	extent.	
	
In	conclusion,	our	study	does	not	provide	strong	evidence	to	support	previous	findings	that	LRRK2	
and	PARK16	variants	may	interact	in	determining	risk	of	PD	for	a	given	individual.	However,	there	
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was	some	degree	of	concordance	between	our	interaction	findings	and	those	that	were	previously	
reported,	with	the	caveat	that	our	results	were	much	weaker	than	the	strong	LRRK2-PARK16	
interaction	that	was	previously	reported7.	Larger	series	will	be	needed	to	resolve	whether	a	true	
LRRK2-PARK16	interaction	occurs.	Of	note,	even	with	the	large	GEoPD	sample	size,	which	we	have	
accrued	to	perform	current	study,	we	are	likely	underpowered	to	detect	weaker	interaction	effects;	
however	such	studies	will	be	critical	if	we	are	to	understand	the	role	of	gene-gene	interaction	in	
disease	susceptibility.		
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Supplementary	Table	1:	Descriptive	Statistics	of	Individual	Sites	
Site	 Country	
No.	of		PD	
Cases	
No.	of	
Controls	
No.	(%)	of	Males	
in	PD	cases	
No.	(%)	of	
Males	in	
Controls	
Mean(SD)	
Age	in	PD	
Cases	
Mean(SD)	Age	
in	controls	
Diagnostic	
Criteria	
Caucasian	series	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
Aasly	 Norway	 527	 510	 314	(59%)	 276	(54%)	 73.8	(10.6)	 71.1	(10.6)	 UKPDBB	
Annesi	 Italy	 178	 182	 98	(53.6%)	 93	(51.1%)	 65.6	(9)	 61.9	(9)	 	UKPDBB	
Bozi	 Greece	 113	 104	 55	(48.7%)	 49	(47.1%)	 75.7	(7.3)	 73.0	(7.3)	 UKPDBB	
Brice	 France	 272	 231	 168	(61.8%)	 132	(57.1%)	 57.7	(11.5)	 57.8	(11.5)	 UKPDBB	
Garraux	 Belgium	 64	 14	 34	(53.1%)	 7	(50%)	 70.5	(9.6)	 66.1	(9.6)	 	UKPDBB	
Hadjigeorgiou	 Greece	 313	 328	 170	(54.3%)	 169	(51.5%)	 64.7	(9.8)	 63.2	(9.8)	 	UKPDBB	
Lynch/Ross	 Ireland	 328	 345	 183	(55.8%)	 121	(35.1%)	 68.1	(10.3)	 73.4	(10.3)	 UKPDBB	
Maragonore	 USA	 801	 223	 491	(62.4%)	 109	(62.6%)	 61.7	(11)	 NA	 	UKPDBB	
Mellick	 Australia	 893	 916	 556	(62.3%)	 373	(40.7%)	 73.6	(11.1)	 71.7	(11.1)	 Bower	
Morrison	 England	 723	 349	 490	(67.8%)	 87	(25.1%)	 66.2	(10.8)	 NA	 	UKPDBB	
Opala/Ross	 Poland	 291	 255	 186	(63.9%)	 113	(44.3%)	 70.9	(10.5)	 65.0	(10.5)	 UKPDBB	
van	Broeckhoven	 Belgium	 497	 510	 286	(57.1%)	 214	(42.1%)	 68.1	(10.6)	 64.7	(10.6)	 Pals/	Gelb	
Wirdefeldt	 Sweden	 77	 194	 41	(53.2%)	 93	(47.9%)	 72.3	(8.4)	 71.0	(8.4)	 UKPDBB	
Wszolek/Ross	 USA	 692	 827	 440	(63.6%)	 354	(42.8%)	 74.6	(11.4)	 70.1	(11.4)	 UKPDBB	
Total	 		 7715	 8261	 		 		 		 		 		
Asian	series	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
Chung	 Korea	 368	 333	 153	(41.6%)	 140	(42%)	 58	(9.6)	 66.1	(9.6)	 	UKPDBB	
Lin	 Taiwan	 160	 160	 80	(50%)	 80	(50%)	 70.8	(9.8)	 70.8	(9.8)	 UKPDBB	
Mok	 China	 259	 78	 158	(61.5%)	 52	(66.7%)	 64.8	(4.1)	 62.5	(4.1)	 	UKPDBB	
Satake/Toda	 Japan	 988	 2521	 405	(41.0%)	 1525	(60.5%)	 58.8	(10.1)	 49.9	(14.2)	 	UKPDBB	
Tan	 Singapore	 171	 181	 110	(64.3%)	 112	(61.9%)	 62.4	(9.3)	 45.2	(9.3)	 UKPDBB	
Total	 		 1946	 3273	 		 		 		 		 		
	
No.=	number,	NA	indicates	that	data	was	unavailable	
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Supplementary	Table	2:	Associations	and	Minor	Allele	Frequency	(MAF)	of	individual	LRRK2	and	PARK16	variants	with	risk	of	PD	in	
Caucasian	and	Asian	Series.	MAF	was	calculated	separately	for	Asian	and	Caucasian	series.		
Caucasian	Series	 	 	 	 	
SNP	 MAF	 Minor	Allele	 OR	 Pvalue	
LRRK2	rs1491946	 21.2%	 C	 1.16	(1.10	,1.24)	 <0.001	
LRRK2	rs7133914	 6.9%	 A	 0.93	(0.81	,1.08)	 0.36	
PARK16	rs708273	 42.6%	 T	 1.03	(0.97	,1.09)	 0.32	
PARK16	rs708725	 48.4%	 C	 0.91	(0.86	,0.97)	 0.004	
PARK16	rs823139	 12.0%	 T	 0.91	(0.84	,1.00)	 0.038	
PARK16	rs823156	 18.2%	 G	 0.94	(0.87	,1.01)	 0.09	
PARK16	rs11240572	 3.3%	 A	 1.09	(0.93	,1.28)	 0.28	
Asian	Series	 	 	 	 	
SNP	 MAF	 Minor	Allele	 OR	 Pvalue	
LRRK2	rs1491946	 31.8%	 C	 1.10	(1.00	,1.21)	 0.03	
PARK16	rs708723	 14.0%	 T	 1.76	(1.30	,2.35)	 <0.001	
PARK16	rs708725	 47.3%	 C	 0.82	(0.75	,0.90)	 <0.001	
PARK16	rs823139	 14.1%	 T	 0.78	(0.69	,0.88)	 <0.001	
PARK16	rs823156	 20.7%	 G	 0.76	(0.68	,0.85)	 <0.001	
PARK16	rs11240572	 14.7%	 A	 0.78	(0.68	,0.89)	 <0.001	
	
OR	(Odds	Ratio)	
Supplementary	Table	3:	Evaluation	of	interactions	of	LRRK2	rs1491942	and	PARK16	variants	with	regard	to	susceptibility	to	Parkinson’s	
disease	in	the	Combined	Series	
LRRK2	
Variant/Genotype	
PARK16	
Variant/Genotype	
Sample	genotype	count	
and	frequency	 Test	of	Association	OR	 p-value	
Models	for	the	LRRK2	and	
PARK16	SNPs	and	Test	of	
Interaction	Results		
	 	 	 	 	 	
LRRK2	rs1491942	 rs708273	 		 		 		 Additive/Additive	Model	
GG	 GG	 2601	(21.7%)	 1.00	(reference)		 N/A	 OR:	1.0	(0.9,	1.11)	
GG	 GT	 3288	(27.5%)	 1.02	(0.92,	1.10)	 0.75	 p=0.98	
GG	 TT	 1185	(9.9%)	 1.02	(0.9,	1.15)	 0.75	 	
GC	 GG	 1725	(14.4%)	 1.11	(0.94,	1.30)	 0.21	 Heterogeneity:	I2=0,	p=0.49	
GC	 GT	 1824	(15.2%)	 1.08	(0.94,	1.24)	 0.25	 	
GC	 TT	 673	(5.6%)	 1.2	(1.04,	1.37)	 0.011	 	
CC	 GG	 315	(2.6%)	 1.11	(0.9,	1.35)	 0.32	 	
CC	 GT	 260	(2.2%)	 1.37	(1.06,	1.78)	 0.018	 	
CC	 TT	 93	(0.8%)	 1.64	(1.21,	2.22)	 0.001	 	
LRRK2	rs1491942	 rs708725	 		 		 		 Additive/Additive	Model	
GG	 TT	 2291	(15.8%)	 1.00	(reference))	 N/A	 OR:	0.98	(0.90,	1.06)	
GG	 TC	 3884	(26.7%)	 0.85	(0.76,	0.95)	 0.00365	 p=0.55	
GG	 CC	 2066	(14.2%)	 0.82	(0.72,	0.94)	 0.00332	 	
GC	 TT	 1579	(10.9%)	 1.22	(1.06,	1.39)	 0.00418	 Heterogeneity:	I2=0,	p=0.12	
GC	 TC	 2510	(17.3%)	 0.9	(0.8,	1.02)	 0.0968	 	
GC	 CC	 1266	(8.7%)	 0.91	(0.78,	1.06)	 0.237	 	
CC	 TT	 249	(1.7%)	 1.38	(1.05,	1.82)	 0.0227	 	
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CC	 TC	 448	(3.1%)	 1.14	(0.92,	1.41)	 0.232	 	
CC	 CC	 228	(1.6%)	 1.15	(0.85,	1.54)	 0.372	 	
LRRK2	rs1491942	 rs823139	 		 		 		 Additive/Additive	Model	
GG	 GG	 6825	(43.6%)	 1.00	(reference)	 N/A	 OR:	1.01	(0.92,	1.11)	
GG	 GT	 1945	(12.4%)	 0.82	(0.74,	0.92)	 0.00036	 p=0.87	
GG	 TT	 144	(0.9%)	 1.08	(0.76,	1.53)	 0.663	 	
GC	 GG	 4331	(27.7%)	 1.12	(1.04,	1.22)	 0.00483	 Heterogeneity:	I2=0,	p=0.56	
GC	 GT	 1295	(8.3%)	 0.91	(0.8,	1.03)	 0.154	 	
GC	 TT	 103	(0.7%)	 1.08	(0.72,	1.62)	 0.702	 	
CC	 GG	 762	(4.9%)	 1.35	(1.15,	1.58)	 0.000244	 	
CC	 GT	 218	(1.4%)	 1.25	(0.94,	1.66)	 0.127	 	
CC	 TT	 16	(0.1%)	 0.7	(0.25,	1.96)	 0.491	 	
LRRK2	rs1491942	 rs823156	 		 		 		 Additive/AdditiveModel	
GG	 AA	 5734	(37.6%)	 1.00	(reference)	 N/A	 OR:	0.99	(0.88,	1.11)	
GG	 AG	 2580	(16.9%)	 0.89	(0.81,	0.98)	 0.0228	 p=0.83	
GG	 GG	 346	(2.3%)	 0.76	(0.6,	0.96)	 0.0204	 	
GC	 AA	 3687	(24.2%)	 1.14	(1.05,	1.24)	 0.00316	 Heterogeneity:	I2=33,	p=0.56	
GC	 AG	 1681	(11%)	 0.98	(0.87,	1.1)	 0.679	 	
GC	 GG	 234	(1.5%)	 0.95	(0.72,	1.27)	 0.744	 	
CC	 AA	 635	(4.2%)	 1.32	(1.11,	1.57)	 0.00148	 	
CC	 AG	 285	(1.9%)	 1.29	(1.01,	1.67)	 0.0453	 	
CC	 GG	 55	(0.4%)	 0.97	(0.54,	1.75)	 0.92	 	
LRRK2	rs1491942	 rs11240572	 		 		 		 Additive/Dominant	Model	
GG	 CC	 7839	(50%)	 1.00	(reference)	 N/A	 OR:	0.87	(0.74,	1.01)	
GG	 CA+AA	 1095	(7%)	 0.99	(0.86,	1.13)	 0.844	 p=0.069	
GC	 CC	 4903	(31.3%)	 1.14	(1.06,	1.23)	 0.000512	 	
GC	 CA+AA	 834	(5.3%)	 0.91	(0.78,	1.06)	 0.234	 Heterogeneity:	I2=0,	p=0.99	
CC	 CC	 834	(5.3%)	 1.39	(1.19,	1.62)	 2.16E-05	 	
CC	 CA+AA	 167	(1.1%)	 1.13	(0.82,	1.57)	 0.447	 		
	
	
OR	(Odds	Ratio),	Tests	of	Interaction	presents	results	of	Fixed	Effects	Model	with	OR	and	95%	Confidence	Interval	(CI),	Models	were	either	
LRRK2	Additive/PARK16	Additive,	LRRK2	Additive/PARK16	Dominant,	or	LRRK2	Dominant/PARK16	Dominant	(when	MAF<15%,	then	
Dominant	scheme	was	used)	
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Supplementary	Table	4:	Evaluation	of	interactions	of	LRRK2	rs1491942	and	PARK16	variants	with	regard	to	susceptibility	to	Parkinson’s	
disease	in	the	Caucasian	Series	
	
LRRK2	
Variant/Genotype	
PARK16	
Variant/Genotype	
Sample	genotype	
count	and	
frequency	
Test	of	Association	
OR	 p-value	
Models	for	the	LRRK2	and	
PARK16	SNPs	and	Test	of	
Interaction	Results		
	 	 	 OR	 p-value	 	
LRRK2	rs1491942	 rs708273	 		 		 		 Additive/AdditiveModel	
GG	 GG	 2091	(20.2%)	 1.00	(reference)	 N/A	 OR:		1.0	(0.88,	1.14)	
GG	 GT	 3203	(30.9%)	 1.02	(0.91,	1.14)	 0.72	 p=0.95	
GG	 TT	 1130	(10.9%)	 1.14	(0.99,	1.33)	 0.074	 	
GC	 GG	 1111	(10.7%)	 1.12	(0.96,	1.3)	 0.15	 Heterogeneity:	I2=0,	p=0.48	
GC	 GT	 1730	(16.7%)	 1.19	(1.04,	1.36)	 0.009	 	
GC	 TT	 625	(6%)	 1.08	(0.9,	1.30)	 0.39	 	
CC	 GG	 155	(1.5%)	 1.61	(1.15,	2.27)	 0.006	 	
CC	 GT	 230	(2.2%)	 1.55	(1.17,	2.06)	 0.002	 	
CC	 TT	 74	(0.7%)	 1.52	(0.93,	2.48)	 0.092	 	
LRRK2	rs1491942	 rs708725	 		 		 		 Additive/Additive	Model	
GG	 TT	 1626	(17.1%)	 1.00	(reference)	 N/A	 OR:	:1.02	(0.88,	1.18)	
GG	 TC	 2728	(28.7%)	 0.89	(0.78,	1.01)	 0.066	 p=0.83	
GG	 CC	 1540	(16.2%)	 0.85	(0.73,	0.99)	 0.042	 	
GC	 TT	 960	(10.1%)	 1.17	(1.00,	1.38)	 0.058	 Heterogeneity:	I2=0,	p=0.16	
GC	 TC	 1481	(15.6%)	 0.95	(0.82,	1.10)	 0.51	 	
GC	 CC	 770	(8.1%)	 0.96	(0.79,	1.16)	 0.66	 	
CC	 TT	 116	(1.2%)	 1.33	(0.9,	1.96)	 0.16	 	
CC	 TC	 194	(2%)	 1.52	(1.11,	2.08)	 0.009	 	
CC	 CC	 100	(1.1%)	 1.26	(0.8,	1.98)	 0.33	 	
LRRK2	rs1491942	 rs823139	 		 		 		 Additive/Additive	Model	
GG	 GG	 5035	(48.1%)	 1.00	(reference)	 N/A	 OR:	0.99	(0.90,	1.10)	
GG	 GT	 1374	(13.1%)	 0.86	(0.76,	0.98)	 0.018	 p=0.59	
GG	 TT	 91	(0.9%)	 1.11	(0.72,	1.71)	 0.63	 	
GC	 GG	 2708	(25.9%)	 1.11	(1.01,	1.22)	 0.03	 Heterogeneity:	I2=0,	p=0.54	
GC	 GT	 742	(7.1%)	 0.97	(0.83,	1.14)	 0.71	 	
GC	 TT	 58	(0.6%)	 1.19	(0.70,	2.02)	 0.52	 	
CC	 GG	 361	(3.4%)	 1.46	(1.17,	1.83)	 <0.001	 	
CC	 GT	 91	(0.9%)	 1.69	(1.08,	2.64)	 0.021	 	
CC	 TT	 10	(0.1%)	 0.65	(0.18,	2.32)	 0.50	 	
LRRK2	rs1491942	 rs823156	 		 		 		 Additive/Additive	Model	
GG	 AA	 4151	(41.2%)	 1.00	(reference)	 N/A	 OR:	0.95	(0.86,	1.05)	
GG	 AG	 1882	(18.7%)	 0.94	(0.84,	1.05)	 0.27	 p=0.87	
GG	 GG	 209	(2.1%)	 0.87	(0.66,	1.16)	 0.35	 	
GC	 AA	 2278	(22.6%)	 1.12	(1.01,	1.25)	 0.034	 Heterogeneity:	I2=23,	p=0.37	
GC	 AG	 996	(9.9%)	 1.12	(0.97,	1.30)	 0.11	 	
GC	 GG	 108	(1.1%)	 0.84	(0.56,	1.24)	 0.38	 	
CC	 AA	 301	(3%)	 1.48	(1.15,	1.89)	 0.002	 	
CC	 AG	 124	(1.2%)	 1.59	(1.09,	2.32)	 0.016	 	
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CC	 GG	 17	(0.2%)	 0.84	(0.31,	2.22)	 0.72	 	
LRRK2	rs1491942	 rs11240572	 		 		 		 Additive/Dominant	Model	
GG	 CC	 6094	(57.9%)	 1.00	(reference)	 N/A	 OR:0.89	(0.68,	1.17)	
GG	 CA+AA	 434	(4.1%)	 1.15	(0.94,	1.40)	 0.17	 p=0.25	
GC	 CC	 3300	(31.4%)	 1.12	(1.03,	1.23)	 0.009	 	
GC	 CA+AA	 223	(2.1%)	 1.06	(0.81,	1.40)	 0.67	 Heterogeneity:	I2=0,	p=0.87	
CC	 CC	 433	(4.1%)	 1.51	(1.23,	1.86)	 <0.001	 	
CC	 CA+AA	 33	(0.3%)	 1.65	(0.8,	3.40)	 0.17	 		
	
OR	(Odds	Ratio),	Tests	of	Interaction	presents	results	of	Fixed	Effects	Model	with	OR	and	95%	Confidence	Interval	(CI),	Models	were	either	
LRRK2	Additive/PARK16	Additive,	LRRK2	Additive/PARK16	Dominant,	or	LRRK2	Dominant/PARK16	Dominant	(when	MAF<15%,	then	
Dominant	scheme	was	used)	
	
	
Supplementary	Table	5:	Evaluation	of	interactions	of	LRRK2	rs1491942	and	PARK16	variants	with	regard	to	susceptibility	to	Parkinson’s	
disease	in	the	Asian	Series	
	
LRRK2	
Variant/Genotype	
PARK16	
Variant/Genotype	
Sample	
genotype	count	
and	frequency	
Test	of	Association	
OR	 p-value	
Models	for	the	LRRK2	and	
PARK16	SNPs	and	Test	of	
Interaction	Results		
LRRK2	rs1491942	 rs708723	 		 		 		 Additive/Additive	Model	
GG	 GG	 510	(31.6%)	 1.00	(reference)	 N/A	 OR:			1.1	(0.89,	1.36)	
GG	 GT	 85	(5.3%)	 2.72	(1.53,	4.83)	 <0.001	 p=0.40	
GG	 TT	 55	(3.4%)	 1.96	(0.97,	3.95)	 0.060	 	
GC	 GG	 614	(38%)	 1.01	(0.8,	1.28)	 0.91	 Heterogeneity:	I2=0,	p=0.43	
GC	 GT	 94	(5.8%)	 4.11	(2.21,	7.65)	 <0.001	 	
GC	 TT	 48	(3%)	 2.94	(1.31,	6.56)	 0.009	 	
CC	 GG	 160	(9.9%)	 1.15	(0.81,	1.65)	 0.43	 	
CC	 GT	 30	(1.9%)	 2.69	(1.07,	6.8)	 0.036	 	
CC	 TT	 19	(1.2%)	 4.41	(1.22,	15.9)	 0.024	 	
LRRK2	rs1491942	 rs708725	 		 		 		 Additive/Additive	Model	
GG	 TT	 665	(13.3%)	 1.00	(reference)	 N/A	 OR:	0.	97	(0.86,	1.11)	
GG	 TC	 1156	(23.1%)	 0.76	(0.62,	0.94)	 0.01	 p=0.69	
GG	 CC	 526	(10.5%)	 0.74	(0.58,	0.96)	 0.0237	 	
GC	 TT	 619	(12.4%)	 1.25	(0.99,	1.58)	 0.0614	 Heterogeneity:	I2=0,	p=0.19	
GC	 TC	 1029	(20.6%)	 0.8	(0.65,	0.99)	 0.0411	 	
GC	 CC	 496	(9.9%)	 0.82	(0.63,	1.06)	 0.124	 	
CC	 TT	 133	(2.7%)	 1.35	(0.9,	2)	 0.142	 	
CC	 TC	 254	(5.1%)	 0.85	(0.62,	1.16)	 0.302	 	
CC	 CC	 128	(2.6%)	 1	(0.67,	1.51)	 0.982	 	
LRRK2	rs1491942	 rs823139	 		 		 		 Additive/Additive	Model	
GG	 GG	 1790	(34.6%)	 1.00	(reference)	 N/A	 OR:	1.08	(0.93,	1.26)	
GG	 GT	 571	(11%)	 0.72	(0.58,	0.89)	 0.00223	 p=0.31	
GG	 TT	 53	(1%)	 1	(0.55,	1.81)	 0.993	 	
GC	 GG	 1623	(31.4%)	 1.12	(0.97,	1.29)	 0.133	 Heterogeneity:	I2=0,	p=0.23	
GC	 GT	 553	(10.7%)	 0.81	(0.66,	1)	 0.0508	 	
GC	 TT	 45	(0.9%)	 0.92	(0.48,	1.74)	 0.791	 	
CC	 GG	 401	(7.8%)	 1.21	(0.96,	1.52)	 0.112	 	
CC	 GT	 127	(2.5%)	 0.96	(0.65,	1.42)	 0.839	 	
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CC	 TT	 6	(0.1%)	 0.79	(0.14,	4.51)	 0.791	 	
LRRK2	rs1491942	 rs823156	 		 		 		 Additive/Additive	Model	
GG	 AA	 1583	(30.6%)	 1.00	(reference)	 N/A	 OR:		0.99	(0.82,	1.12)		
GG	 AG	 698	(13.5%)	 0.76	(0.62,	0.93)	 0.00658	 p=0.92	
GG	 GG	 137	(2.6%)	 0.53	(0.35,	0.82)	 0.00388	 	
GC	 AA	 1409	(27.2%)	 1.14	(0.97,	1.33)	 0.103	
Heterogeneity:	I2=16	
p=0.29		
GC	 AG	 685	(13.2%)	 0.74	(0.61,	0.91)	 0.00352	 	
GC	 GG	 126	(2.4%)	 0.98	(0.64,	1.52)	 0.94	 	
CC	 AA	 334	(6.5%)	 1.13	(0.88,	1.46)	 0.326	 	
CC	 AG	 161	(3.1%)	 1.02	(0.72,	1.46)	 0.893	 	
CC	 GG	 38	(0.7%)	 0.92	(0.43,	1.99)	 0.835	 	
LRRK2	rs1491942	 rs11240572	 		 		 		 Additive/Dominant	Model	
GG	 CC	 1745	(33.9%)	 1.00	(reference)	 N/A	 OR:0.92	(0.75,	1.13)	
GG	 CA+AA	 661	(12.8%)	 0.85	(0.7,	1.04)	 0.116	 p=0.42	
GC	 CC	 1603	(31.1%)	 1.17	(1.01,	1.35)	 0.039	 	
GC	 CA+AA	 611	(11.9%)	 0.82	(0.67,	1.01)	 0.0633	 Heterogeneity:	I2=0,	p=0.87	
CC	 CC	 401	(7.8%)	 1.23	(0.97,	1.55)	 0.0825	 	
CC	 CA+AA	 134	(2.6%)	 1	(0.68,	1.45)	 0.981	 		
	
OR	(Odds	Ratio),	Tests	of	Interaction	presents	results	of	Fixed	Effects	Model	with	OR	and	95%	Confidence	Interval	(CI),	Models	were	either	
LRRK2	Additive/PARK16	Additive,	LRRK2	Additive/PARK16	Dominant,	or	LRRK2	Dominant/PARK16	Dominant	(when	MAF<15%,	then	
Dominant	scheme	was	used)	
	
	
	
	
	
	
Supplementary	Table	6:	Stratified	Analysis	of	Effect	of	LRRK2	rs1491942	on	Carriers	and	Non-carriers	of	PARK16	rs11240572	Minor	Allele	
	 		 PARK16	rs11240572	allele	 		 		
	 Carriers	 		 		 Non-Carriers	 		 		
Ethnic	Series	 LRRK2	OR	(95%	CI)		 pval	 n	 LRRK2	OR	(95%	CI)		 pval	 n	
Asian		 1.02	(0.85	,1.22)	 0.82	 1409	 1.13	(1.58	,1.10)	 0.17	 3766	
Caucasian	 1.04	(0.80	,1.35)	 0.79	 697	 1.17	(1.10	,1.25)	 												<0.000	 9995	
Combined	 1.03	(0.88	,1.19)	 0.73	 2106	 1.15	(0.10	,1.22)	 <0.000	 13761	
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Supplementary	Table	7:	Evaluation	of	interactions	of	LRRK2	rs7133914	and	PARK16	variants	with	regard	to	susceptibility	to	Parkinson’s	
disease	in	the	Caucasian	Series	
	
LRRK2	
Variant/Genotype	
PARK16	
Variant/Genotype	
sample	
genotype	
count	and	
frequency	
Test	of	Association	
OR	 p-value	
Models	for	the	LRRK2	and	
PARK16	SNPs	and	Test	of	
Interaction	Results	
		 		 		 		 		 		
LRRK2	rs7133914	 rs708273	 		 		 		 Dominant/Additive	Model	
GG	 GG	 1788	(27.9%)	 1.00	(reference)	 N/A	 OR:	0.92	(0.69,	1.20)	
GG	 GT	 3764	(58.7%)	 1.02	(0.91,	1.16)	 0.71	 p=0.54	
GG	 TT	 288	(4.5%)	 1.10	(0.94,	1.30)	 0.22	 	
GA+AA	 GG	 577	(9%)	 1.07	(0.83,	1.39)	 0.60	 Heterogeneity:	I2=35	p=0.11	
GA+AA	 GT	 1361	(22.7%)	 0.88	(0.71,	1.10)	 0.26	 	
GA+AA	 TT	 3834	(63.9%)	 0.96	(0.69,	1.33)	 0.79	 	
LRRK2	rs7133914	 rs708725	 		 		 		 Dominant/Additive	Model	
GG	 TT	 206	(3.4%)	 1.00	(reference)	 N/A	 Additive	Model	
GG	 TC	 600	(10%)	 0.92	(0.8,	1.06)	 0.24	 OR:	0.85(0.61,	1.18)	
GG	 CC	 4317	(66.4%)	 0.79	(0.66,	0.94)	 0.008	 p=0.33	
GA+AA	 TT	 1306	(20.1%)	 0.89	(0.66,	1.20)	 0.44	 	
GA+AA	 TC	 688	(10.6%)	 0.72	(0.57,	0.91)	 0.006	 Heterogeneity:	I2=0,	p=0.61	
GA+AA	 CC	 188	(2.9%)	 1.02	(0.74,	1.40)	 0.91	 	
LRRK2	rs7133914	 rs823139	 		 		 		 Dominant/Additive	Model	
GG	 GG	 3658	(58.1%)	 1.00	(reference)	 N/A	 Additive	Model	
GG	 GT	 1799	(28.6%)	 0.92	(0.81,	1.05)	 0.22	 OR:	1.20(0.97,	1.48)	
GG	 TT	 573	(9.1%)	 1.00	(0.65,	1.53)	 0.99	 p=0.096	
GA+AA	 GG	 270	(4.3%)	 0.98	(0.83,	1.15)	 0.80	 	
GA+AA	 GT	 5486	(84%)	 0.72	(0.53,	0.98)	 0.034	 Heterogeneity:	I2=13,	p=0.25	
GA+AA	 TT	 169	(2.6%)	 1.26	(0.34,	4.64)	 0.73	 	
LRRK2	rs7133914	 rs823156	 		 		 		 Dominant/Additive	Model	
GG	 AA	 848	(13%)	 1.00	(reference)	 N/A	 Additive	Model	
GG	 AG	 26	(0.4%)	 1.00	(0.89,	1.13)	 0.96	 OR:	0.88	(0.72,	1.09)	
GG	 GG	 5281	(80.9%)	 0.83	(0.60,	1.13)	 0.24	 p=0.25	
GA+AA	 AA	 370	(5.7%)	 0.97	(0.81,	1.17)	 0.77	 	
GA+AA	 AG	 805	(12.3%)	 0.79	(0.60,	1.03)	 0.078	 Heterogeneity:I2=0.	p=0.74	
GA+AA	 GG	 70	(1.1%)	 1.13	(0.49,	2.64)	 0.77	 	
LRRK2	rs7133914	 rs11240572	 		 		 		 Dominant/Dominant	Model	
GG	 CC	 1730	(16.7%)	 1.00	(reference)	 N/A	 OR:	1.20	(0.70,	2.07)	
GG	 CA+AA	 625	(6%)	 1.05	(0.84,	1.30)	 0.69	 p=0.51	
GA+AA	 CC	 155	(1.5%)	 0.91	(0.78,	1.06)	 0.25	 	
GA+AA	 CA+AA	 230	(2.2%)	 1.15	(0.71,	1.86)	 0.57	 Heterogeneity:	I2=0,	p=0.61	
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Figure	1:	Forest	Plot	of	LRRK2	rs1491942	and	PARK16	rs1124072	in	PD	cases	and	controls	in	Caucasian,	Asian,	and	combined	series	
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Abstract	
Introduction:	The	growing	life	expectancy	increases	the	risk	for	comorbidities.	Emerging	evidence	
showed	an	involvement	of	immune	dysfunction	in	seemingly	diverse	phenotypes	such	as	Parkinson	
disease	(PD)	and	type-1	diabetes	(T1D).	We	examined	differences	in	diabetes	disease	pathogenesis	
between	PD	and	non-PD	patients.	We	determined	the	prevalence	and	compared	the	diabetic	end-
points	in	T1D	patients	with	or	without	PD.	
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Methods:	We	performed	an	epidemiological	study	with	multivariable	logistic	regression.	Data	was	
retrieved	from	the	German/Austrian	prospective,	multicenter	diabetes	patient	follow-up	registry,	
DPV.	In	total,	19,864	T1D	patients	aged	≥40	years	were	analyzed;	111	patients	had	a	PD	diagnosis	
and/or	used	specific	anti-Parkinson	medication.	We	compared	clinical	and	biological	endpoints	
between	PD	and	non-PD	T1D	patients.	To	adjust	for	demographic	differences,	multivariable	
regression	models	with	age,	sex	and	duration	of	diabetes	as	covariates	were	used.		
Results:	PD	patients	were	significantly	older	(74.2	vs	55.7	years,	<0.0001)	and	had	longer	diabetes	
duration	than	non-PD	patients	(30.1	vs	21.9	years,	p<0.0001).	Demographically-adjusted	analyses	
showed	a	significantly	increased	risk	for	renal	failure	for	patients	with	PD	and	T1D	(OR	(95%CI):	3.3	
(1.8-6.0),	p<0.0001).	Furthermore,	increased	risk	for	dementia	(OR	(CI):	2.0	(1.2-3.3),	p=0.005),	
stroke	(1.7	(1.1-2.8),	p=0.028),	and	as	well	as	a	longer	duration	of	hospital	stay	(5.19±0.18	vs	
3.08±0.01,	p<0.001)	was	observed	for	PD	patients.			
Conclusion:	An	increased	risk	for	renal	failure,	dementia	and	stroke	was	observed	in	patients	with	
T1D	and	PD	as	compared	to	patients	with	T1D	alone.	The	clinical	end-points	should	be	taken	into	
consideration	in	routine	clinical	practice.		
Short	summary:	A	large	scale	retrospective	cohort	study	comparing	comorbidies	of	Parkinson's	
disease	patients	with	neurologically	normal	patients	within	a	type	1	diabetes	population.	
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Introduction:	
Parkinson’s	disease	(PD)	is	one	of	the	most	common	neurodegenerative	disorders,	affecting	
between	0.1	and	3%	of	the	general	population,	and	second	in	prevalence	only	to	Alzheimer’s	disease	
[1].	The	disease	is	characterized	by	a	loss	of	dopaminergic	neurons	in	the	substantia	nigra,	resulting	
in	reduced	striatal	dopamine	content,	which	leads	to	decline	in	the	motor	systems	[2].	The	non-
motor	symptoms	such	as	depression,	gastrointestinal	dysfunction,	and	autonomic	dysfunction	
precede	onset	of	motor	symptoms	[2],	and	severity	of	non-	motor	symptoms	increases	with	
advancing	disease	[3,4].	While	the	degeneration	of	dopaminergic	neurons	remains	central	to	disease	
pathogenesis,	non-dopaminergic	neurons	(such	as	norepinephrinergic,	cholinergic	and	
serotoninergic	neurons)	in	the	basal	forebrain,	locus	coeruleus,	and	raphei	nuclei	respectively	are	
also	affected	indicating	that	disease	progresses	first	through	lower	brainstem	before	spreading	to	
the	basal	ganglia	and	cortex	[4].	
The	exact	mechanism	of	neuronal	decay	in	PD	is	not	fully	understood,	although	emerging	evidence	
links	abnormal	protein	misfolding,	mitochondrial	dysfunction,	and	oxidative	stress	to	PD	
pathogenesis	[5].	Furthermore,	neuroinflammatory	mechanisms	such	as	microglia	activation,	
astrogliosis	and	lymphocytic	infiltration	may	also	contribute	to	the	neuronal	degeneration	[6].		It	is	
still	not	resolved	whether	neuroinflammation	is	a	consequence	or	cause	of	cell	death.	Nevertheless,	
emerging	evidences	generated	from	postmortem,	epidemiological	and	genetic	studies	indicate	that	
neuroinflammation	can	be	a	risk	factor	for	PD.	For	example,	in	post-mortem	studies	of	PD	patients,	
neuroinflammatory	markers	such	as	tumor	necrosis	factor	(TNFα),	interleukin	(IL)	1β,	6,	and	2	were	
found	in	the	striatum	and	substantia	nigra,	suggesting	that	immune	response	plays	a	significant	role	
in	the	disease	progression	[2].	Candidate	gene	studies	assessing	genetic	variability	of	
neuroinflammation	genes	such	as	(TNF,	IFNɤ,	IL)	consistently	showed	increased	risk	for	PD	[7,8].		
Likewise,	data	generated	from	epidemiological	studies	also	showed	protective	effect	of	anti-
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inflammatory	drugs	for	PD	patients	[9].	Interestingly,	data	generated	from	genome	wide	association	
studies	(GWAS)	in	PD	established	the	role	of	HLA	locus	in	PD,	thus	underscoring	an	involvement	of	
neuroinflammation	in	PD	[8,10].	In	addition,	alpha-synuclein	deposits	have	been	discovered	in	the	
pancreas	in	PD	patients,	and	the	protein	itself	has	been	implicated	in	binding	of	insulin-secretory	
granules	and	in	insulin	secretion	inhibition	[11].	The	developing	body	of	evidence	suggests	that	the	
two	diseases	interact	at	on	both	the	genetic	and	functional	level	[12].		
The	role	of	inflammatory	mediators	contributing	to	the	pathogenesis	of	autoimmune	disorders	such	
as	T1D	is	much	wider	than	previously	anticipated	because	of	the	polygenic	nature	of	the	disease	
[13,14].	It	has	been	suggested	that	immune	response,	inflammatory	mediators	such	as	cytokines,	
apart	from	contributing	to	cell	death	also	increases	the	risk	for	neurodegenerative	diseases	[14-16].	
Recent	studies	have	also	shown	that	apoptosis-induced	neuronal	decay	occurs	in	the	brain	of	T1D	
BB/W	rats,	suggesting	that	the	T1D	phenotype	is	related	the	cognitive	impairment	seen	in	the	rat	
models	[17].	
	Given	the	converging	immune	dysfunction	evidence	between	T1D	and	PD	[18,19],	we	aimed	to	
investigate	the	prevalence	and	diabetic	end-points	in	neurologically	normal	T1D	patients	in	
comparison	to	T1D	patients	with	PD.	We	leveraged	the	prospective	diabetes	patient	registry	(DPV)	
cohort	with	over	19000	adult	T1D	patients	to	assess	whether	there	are	clinical	and	epidemiological	
differences	between	the	two	patient	populations.	
Methods:	
The	DPV	initiative	has	been	ethically	approved	by	the	Ethics	Committee	of	Ulm	University,	Germany.	
The	local	review	boards	of	each	participating	clinic,	approved	the	anonymized	data	collection.	
Study	population	
Specialized	diabetes	clinics	in	Germany	and	Austria	document	real-life	clinical	data	on	diabetes	
patients	regularly	in	a	joint	initiative	for	over	20	years	by	using	a	standardized	electronic	record	
system.	The	locally	stored	data	are	transmitted	twice	yearly	in	anonymous	form	to	the	University	of	
Ulm,	Germany	for	central	analyses	as	well	as	benchmarking	[20,21].	All	plausible	data	are	
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aggregated	in	order	to	set-up	the	prospective,	multicenter	diabetes	patient	follow-up	registry,	DPV.	
Up	to	now,	demographic	and	diabetes-related	data	of	453580	patients	with	any	type	of	diabetes	
documented	by	478	clinics	are	available	in	the	registry.	The	DPV	initiative	has	been	approved	by	the	
ethics	committee	of	Ulm	University,	Germany,	and	the	anonymized	data	assessment	by	the	local	
review	board	of	each	participating	clinic.	Until	September	2016,	the	DPV	registry	included	19864	T1D	
patients	aged	40	years	or	older	with	documented	insulin	dosage	who	were	eligible	for	the	study.	To	
identify	patients	with	comorbid	PD,	a	structured	database	search	was	performed	which	was	
described	in	detail	in	the	previous	work	on	PD	in	T2D	patients	[22].	In	brief,	ICD-10-codes	as	well	as	
specific	search	terms	for	a	diagnosis	and/or	treatment	of	PD	were	used	to	select	patients	with	co-
existing	PD.	Excluded	from	analysis	were	patients	with	atypical	or	drug	induced	PD	and	subjects	with	
PD	medication	plus	a	documented	diagnosis/treatment	of	restless-legs-syndrome,	Huntington’s	
disease,	multiple	sclerosis	or	brain	tumor.	Finally,	111	patients	were	identified	having	both	T1D	and	
PD.		
In	case	of	multiple	datasets	per	patient,	data	was	aggregated	over	the	last	year	of	treatment,	
respectively.		
Definitions	of	diabetes	therapy	and	outcome	
Hemoglobin	A1c	(HbA1c)	was	used	to	assess	metabolic	control.	Due	to	the	multicenter	data	
collection,	HbA1c	values	were	mathematically	standardized	to	the	DCCT	reference	range	(20.7-42.6	
mmol/mol,	4.05–6.05%)	using	the	multiple	of	the	mean	(MOM)	method	[23,24].	
Renal	failure	was	diagnosed	in	patients	with	glomerular	filtration	rate	(GFR)<15ml/min/1.73m²	
during	the	last	treatment	year	and/or	renal	transplantation	or	dialysis.	GFR	was	estimated	by	the	
Modification	of	Diet	in	Renal	Disease	(MDRD)	formula	according	to	Silveiro	et	al	[25].	The	definition	
of	renal	failure	is	based	on	the	official	guidelines	from	the	German	Diabetes	Association	(Deutsche	
Diabetes	Gesellschaft)	[26].	
	We	defined	dementia	by	ICD-10	codes,	DSM-IV	and	DSM-5	codes,	or	specific	search	terms	for	a	
diagnosis	of	dementia,	and/or	drugs	specific	for	dementia	treatment.	Data	entries	were	made	by	
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physicians	and	health	care	professionals	at	each	site	based	on	clinically	available	data	from	routine	
care.	Dementia	was	either	already	diagnosed	in	patients,	or	diabetologists	made	the	diagnosis	jointly	
with	neurologists.	This	method	was	previously	applied	in	two	other	publications	on	dementia	and	
diabetes	[22,27].		
ICD-10-codes	or	specific	search	terms	were	used	to	analyze	the	frequency	of	myocardial	infarction,	
stroke	and	diabetic	foot	syndrome.		
Statistical	analysis	
SAS	9.4	(Statistical	Analysis	Software,	SAS	Institute	Inc.,	Cary,	NC,	USA)	was	used	for	all	statistical	
analyses.	First,	descriptive	statistics	were	performed	and	results	are	given	as	median	with	
interquartile	range	or	proportion.	Kruskal-Wallis	test	or	χ2-test	was	applied	to	compare	data.	For	
multiple	comparisons,	p-values	were	adjusted	using	Bonferroni	stepdown	correction	(Holm	
method).		Second,	to	consider	demographic	differences	between	groups,	multivariable	regression	
analyses	with	age,	sex	and	duration	of	diabetes	as	covariates	were	used	to	compare	groups	
regarding	diabetes	therapy	and	outcome.	Separate	models	were	built	for	the	following	outcome	
variables:	i)	glycemic	control,	ii)	type	of	insulin	therapy	and	iii)	specific	parameters	of	diabetes	
outcome	(e.g.	hypertension,	dyslipidemia,	stroke,	renal	failure,	myocardial	infarction).	The	covariate	
‘age’	was	categorized	as	40-<50	y,	50-<60	y,	60-<70	y	and	≥70	y,	and	duration	of	diabetes	was	
divided	into	tertiles.	Linear	regression	with	residual	maximum	likelihood	as	estimation	technique	
was	used	for	continuous	outcome	variables,	logistic	regression	with	maximum	likelihood	estimation	
for	binary	data	and	Poisson	regression	again	with	maximum	likelihood	estimation	for	count	data.	For	
the	outcomes	of	interest	as	determined	by	p-values	in	the	general	analyses,	individual	analyses	
stratified	by	age	groups	was	also	performed.	Between-within	technique	was	used	to	compute	
denominator	degrees	of	freedom.	Based	on	observed	marginal	frequencies,	adjusted	estimates	
(means	±	SEM)	were	calculated.	A	two-sided	p<0.05	was	defined	significant.		
Results:	
Study	Population:	
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Baseline	clinical	characteristics	of	the	patient	population	are	presented	in	Table	1.	Our	T1D	study	
population	has	PD	diagnosis	or	treatment	rate	of	0.6%	(111	PD	patients).	PD	frequencies	change	
between	the	age	groups	(Figure	1).	In	the	youngest	age	category	(40-<50	years),	the	prevalence	is	
0.1%	versus	1.8%	in	the	oldest	age	category	(>=70),	suggesting	that	PD	is	also	age	dependent	in	our	
T1D	cohort	(Figure	1).	In	the	50	to	60	year-olds,	PD	is	more	prevalent	in	T1D	patients	compared	to	
the	general	population	(Figure	1),	whereas	in	the	oldest	age	category	PD	prevalence	tends	to	be	
higher	in	the	general	population	(GP)	than	in	T1D	patients.	Likewise,	we	observed	more	men	than	
women	with	PD	in	the	50-60	age	group	(0.27%	vs	0.16%)	as	well	as	in	the	oldest	age	group	>=70	
(2.0%	vs	1.6%),	and	thus	risk	observed	in	our	cohort	for	PD	is	consistent	with	overall	incidence	
estimates	as	reported	for	PD	worldwide1,	(Figure	2).	Compared	to	national	health	claims	data,	PD	
prevalence	seemed	to	be	similar	in	male	T1D	patients	aged	60	to	<70	years,	whereas	in	the	other	
age	groups	for	both	sexes	PD	prevalence	was	either	lower	(>=70)	or	higher	(50-<60	y)	compared	to	
the	general	population	(Figure	2).	Median	age	of	onset	of	diabetes	was	later	in	T1D	patients	with	PD	
than	in	patients	without	(40.5	vs	34.3	years,	p=0.005).	BMI	was	not	related	to	PD	(Table	1),	in	
analysis	adjusted	for	age,	gender,	and	time	since	onset	of	T1D,	(p=0.73);	PD	patients	had	a	BMI	of	
26.34±0.50	kg/m²	versus	non-PD	patients	of	26.31±0.04	kg/m².		
Comparison	of	metabolic	control	and	diabetes	treatment:	
In	analyses	adjusted	for	age,	gender,	and	diabetes	duration,	we	found	that	PD	and	non-PD	patients	
had	similar	HbA1c	levels.	In	addition,	insulin	therapy,	including	pumps	and	medication	usage,	was	
also	comparable	between	PD	and	non-PD	patients,	with	p-values	>0.05	(Table	2).	Thus,	PD	patients	
did	not	differ	from	non-PD	patients	in	the	control	and	management	of	T1D.	
Comparison	of	Diabetes	Complications:	
In	the	age,	gender,	and	diabetes	duration	adjusted	analyses,	we	found	renal	failure,	stroke,	and	
dementia	at	an	increased	rate	in	PD	patients	as	opposed	to	non-PD	patients,	(Table	2).	The	odds	
ratio	of	renal	failure	occurring	in	PD	patients	was	3.34	(95%	CI:	1.84,	6.05),	with	p-value	<	0.0001.	In	
PD	patients,	the	OR	of	dementia	was	2.03	(1.24,	3.33),	with	p-value=0.005	and	of	stroke	1.73	(1.06,	
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2.82),	with	p-value=0.028.	Hospitalization	was	defined	as	a	categorical	yes/no	variable,	and	there	
was	also	an	increased	odds	of	hospitalization	in	PD	patients,	although	not	statistically	significant	
with	OR	of	1.54	(0.96,	2.46),	p-value=0.076.	However,	duration	of	hospital	stay	was	significantly	
longer	in	PD	patients	(Table	2).	
Microvascular	complications	such	as	retinopathy	and	microalbuminuria	tended	to	be	more	frequent	
in	PD	patients	if	adjusted	for	age,	gender	and	diabetes	duration	(Table	2).	By	contrast,	aside	from	
stroke,	cardiovascular	health	was	comparable	between	the	two	groups,	based	on	dyslipidemia,	
hypertension	and	rates	of	myocardial	infarction	(Table	2).	Furthermore,	diabetic	foot	syndrome	also	
occurred	at	a	similar	rate	between	the	two	groups,	p-value=0.12.		
Age-stratified	analysis:	
Dementia,	stroke,	rate	of	hospitalization,	and	renal	failure	were	selected	for	age-stratified	analysis	
(Table	3).	We	chose	them	based	upon	the	p-values	in	the	regression	models	across	the	entire	study	
population.	In	an	age	dependent	manner,	we	observed	an	increased	risk	for	dementia	(OR=2.48	
(1.38,	4.47),	p-value	=	0.0025),	and	stroke	(OR=2.207	(1.241,	3.925),	p-value=0.007)	in	>70	age	group	
category	(Table	3)	in	PD	patients	compared	to	T1D	subjects	without	PD.	Interestingly,	increased	risk	
of	renal	failure	was	consistently	observed	across	a	wide	spectrum	of	age	groups,	from	40-50	
(OR=10.4	(1.80,	59.9),	p-value=0.009),	to	50-60	age	range	(OR=8.7	(2.25,	33.6),	p-value=0.002),	and	
also	in	the	>70	age	group	(OR=2.25,	0.04)	indicating	renal	dysfunction	as	an	early	prognostic	clinical	
marker	for	PD.	Length	of	hospitalization	(days)	also	increased	with	PD	diagnosis.	In	the	age	group	40-
50y,	duration	of	stay	is	longer	in	PD	patients	compared	to	T1D	patients	without	PD	(4	(3.2,	5.3)	days	
on	average	more	for	PD	patients,	p<0.001).	In	the	50-60y	age	category,	we	see	an	increase	in	
expected	number	of	days	by	1.3	(1.02,	1.75)	days	(p=0.035)	in	PD	patients	versus	neurologically	
normal	patients.	In	the	age	group	60-70y,	we	seen	an	expected	decrease	in	number	days,	0.27	(0.18,	
0.407)	(p<0.001).	In	the	oldest	age	group	>70y,	we	seen	an	expected	increase	in	of	2	days	(1.84,	
2.13),	(p<0.001).		
Discussion:	
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In	this	prospective,	large,	multi-center	study	of	202	separate	sites	across	Germany	and	Austria,	we	
compared	clinical	and	demographic	data	between	patients	with	T1D	and	PD	and	patients	with	only	
T1D.	While	median	age	of	PD	patients	was	dramatically	older;	renal	failure,	stroke	and	dementia	
were	more	frequent	and	duration	of	hospital	stay	was	longer	than	in	non-PD	patients	(median	age	of	
74	versus	56).	Most	other	clinical	endpoints	of	diabetes	management,	including	HbA1C	levels,	were	
comparable	between	the	two	groups.	Of	note,	the	study	found	no	differences	between	BMI	in	the	
two	groups,	suggesting	that	there	is	no	significant	weight	loss	in	PD	patients	due	to	increasing	
nutritional	needs	and	or	decreased	food	intake.	
We	observed	that	although	men	constituted	58%	of	the	T1D	population	in	patients	between	the	
ages	of	40	to	50	years,	the	rate	of	PD	was	higher	in	women	than	in	men	(0.11%	versus	0.08%,	Figure	
2).	However,	in	the	50	to	60	years’	category,	the	rate	of	PD	is	much	higher	in	men	than	in	women,	
(0.27%	to	0.16%),	consistent	with	male	dominance	of	PD	prevalence	in	the	general	population	
(Figure	2).	In	our	study,	we	observed	in	the	middle	age	group	(60-70)	an	increased	frequency	of	PD	
in	female	T1D	patients	besides	a	similar	PD	frequency	in	males	compared	to	the	general	population,	
suggesting	a	potential	gender	dependent	effect	in	patients	with	T1D	and	PD	in	the	middle	age	group	
category.	The	increased	risk	for	stroke,	as	observed	in	our	study,	indicates	that	cerebrovascular	
changes	contribute	to	increased	risk	for	PD.		Interestingly,	a	previously	published	study	observed	an	
increase	prevalence	of	diabetes	and	hypertension	in	PD	[28],	suggesting	that	orthostatic	hypotension	
in	PD	may	contribute	to	disease	risk.	However,	aside	from	stroke	the	cardiovascular	and	circulatory	
systems	were	not	differentially	compromised;	T1D	patients	with	PD	showed	increased	risk	for	renal	
failure	and	dementia.	The	age	stratified	analysis	also	suggested	a	synergistic	effect	between	PD	and	
dementia	that	is	particular	to	the	oldest	age	group	(>70	years),	again	perhaps	due	to	a	worsening	
effect	of	PD	on	dementia.		
Previously,	patients	with	T1D	have	been	shown	to	be	associated	with	increased	risk	for	acute	renal	
failure	[29].	The	causes	of	acute	renal	failure	observed	in	TID	are	more	likely	to	include	chronic	renal	
impairment	and	urinary	tract	infection	among	others	[30].	Interestingly,	recently	published	studies	
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focusing	on	assessing	non-motor	symptoms	in	PD	consistently	highlighted	the	urinary	dysfunction	as	
one	of	the	most	common	non-motor	symptom	observed	in	PD	patients	[31].		The	high	risk	for	renal	
dysfunction	has	been	observed	in	PD	patients	undergoing	non-neurological	surgery	[32].	Renal	
failure	can	be	attributed	to	bladder	dysfunction	that	can	cause	multiple	urinary	symptoms	including	
urgency,	increased	frequency	of	urination,	nocturia,	and	urinary	retention.	Thus	the	convergence	of	
renal	dysfunction	in	both	phenotypes	underscores	the	need	for	close	surveillance	of	renal	function	
in	diabetic	patients.	In	the	age	stratified	analysis,	a	positive	PD	diagnosis	increases	risk	of	developing	
renal	failure	in	the	younger	age	categories,	including	40-50	and	50-60,	thus	suggesting	that	renal	
dysfunction	manifests	during	the	early	phase	of	the	disease.	Mechanistically,	at	least	from	PD	
perspective,	it	has	been	hypothesized	that	a	failure	of	D1	activation	led	to	the	detrusor	overactivity	
(DO),	which	might	underline	overactive	bladder	(OAB)	[33].		Further	studies	using	functional	imaging	
of	dopamine	transporters	are	needed	for	additional	assessment	and	to	explore	the	correlation	
between	urinary	dysfunction	and	nigrostriatal	dysfunction.		
In	our	study,	we	also	observed	increased	risk	for	dementia	in	T1D	with	PD	indicating	that	an	auto-
immune	component	might	underline	the	relationship	between	these	two.	Given	that	dementia	is	a	
common	co-morbidity	of	PD,	the	increased	risk	observed	here	may	tie	into	the	common	diseases	
pathogenesis	of	PD	and	T1D.	Interestingly,	a	recently	published	study	found	a	moderate	level	of	
pleiotropic	enrichment	between	Alzheimer	disease	(AD)	and	auto-immune	diseases	including	T1D	
suggesting	that	probably	shared	genetic	factors	might	contribute	to	the	disease	pathogenesis	
[27,34].		
We	observed	also	a	longer	duration	of	hospital	stay	and	a	trend	towards	a	higher	incidence	of	
hospitalization	in	PD	patients	versus	non-PD	patients,	confirming	the	previously	observed	finding	
that	PD	and	its	complications	(for	example	infections,	falls,	psychiatric	disorders,	and	pneumonia)	
contributing	to	the	complexity	of	patient	care	and	thus	demand	more	hands-on	clinical	care.	We	
observed	similar	results,	however,	in	diabetic	co-morbidities	such	as	stroke,	diabetic	foot	syndrome,	
heart	attacks,	and	retinopathy.	Therefore,	although	care	for	PD	patients	is	more	complicated,	the	
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overall	quality	of	care	is	comparable	and	PD	patients	do	not	suffer	disproportionately	given	their	PD	
diagnosis.	In	the	age-stratified	analysis,	a	PD	diagnosis	generally	increased	length	of	stay,	with	the	
exception	in	the	60-70	age	group.		
In	conclusion,	our	study	highlighted	renal	failure,	stroke,	dementia	and	duration	of	hospital	stay/	
hospitalization	as	important	clinical	end-points	for	patients	with	T1D	and	PD,	and	found	evidence	
that	supports	the	emerging	relationship	between	PD	and	T1D,	and	thus	future	research	in	
delineating	the	clinical	endpoints	for	comorbid	phenotypes	should	be	pursued	to	develop	
personalized	approaches	for	patient	care.		
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Tables:	
	
Table	1	(Table	13):	Characteristics	of	study	population,	Median	with	interquartile	range	or	proportion	
	 All	 PD	 No	PD	 Females	 Males	
N	 19864	 111	 19753	 9075	 10789	
Sex,	%	Male	 54.3%	 54.1%	 54.3%	 	 	
Age,	years	 55.8		
(47.9-66.6)	
74.2		
(64.9-73.3)	
55.7		
(47.9-66.5)	
57.1	
(48.5-68.9)	
54.7		
(47.5-64.9)	
Age	at	DM	
diagnosis,	years	
34.4		
(22.3-46.0)	
40.5	
(28.2-53.2)	
34.3	
(22.3-46.0)	
34.8	
(21.5-48.7)	
34.0	
(22.9-44.6)	
DM	duration,	
years	
22.0		
(10.1-34.9)	
30.1	
(19.9-43.6)	
21.9	
(10.1-34.9)	
22.4	
(10.6-35.4)	
21.5	
(9.7-34.4)	
BMI,	kg/m²	 25.5		
(22.9-28.9)	
26.3		
(23.5-29.3)	
25.5		
(22.9-28.9)	
25.2		
(22.5-29.3)	
25.7		
(23.3-28.7)	
Except	for	BMI	and	sex,	all	p<0.05	for	the	comparison	between	PD	and	non-PD.	Between	females	and	males,	
all	p<0.05.	
	
	
Table	2	(Table	14):	Diabetes	therapy	and	outcome	compared	between	type	1	diabetes	with	or	without	PD	
	 PD	 No	PD	 p-value	
HbA1c,	mmol/mol	 63.0±2.1	 64.4±0.2	 0.49	
Insulin	use,	%	 	 	 	
CT	 23.0	 19.7	 0.38	
MDI	 58.4	 63.5	 0.36	
CSII	 18.6	 16.8	 0.67	
Insulin	dose,	IU/kg*d	 0.635±0.032	 0.619±0.002	 0.61	
Acute	complications,	%	 	 	 	
Hypoglycemia	 	 	 	
Severe	 13.4	 16.5	 0.39	
With	coma	 5.7	 7.9	 0.38	
DKA	 5.0	 5.4	 0.87	
Chronic	complications,	%	 	 	 	
Dyslipidemia	 58.1	 61.0	 0.59	
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Lipid-lowering	drugs	 26.8	 25.9	 0.81	
Hypertension	 23.8	 27.9	 0.32	
Antihypertensiva	 54.4	 47.6	 0.19	
Stroke	 16.2	 10.0	 0.03	
Myocardial	infarction	 12.4	 10.6	 0.50	
Dementia	 16.1	 8.7	 0.005	
Diabetic	foot	syndrome	 15.3	 10.9	 0.12	
Retinopathy	 47.0	 34.8	 0.12	
Microalbuminuria	 31.0	 23.8	 0.12	
Renal	failure	 9.4	 3.0	 <0.001	
Hospital	care	 	 	 	
Frequency,	%	 16.3	 11.3	 0.08	
Duration,	days	per	year	 5.19±0.18	 3.08±0.01	 <0.001	
Data	as	adjusted	mean	with	SEM	or	proportion.	PJ	patient	year,	CT	conventional	therapy,	DKA	diabetic	
ketoacidosis,	MDI	multiple	daily	injections,	CSII	continuous	subcutaneous	insulin	infusion	
	
 
Table	3	(Table	15):	Age-stratified	analysis	for	T1D	with	or	without	PD	
	
Outcome	 40-<50	years	 50-<60	years	 60-<70	years	 >70	years	
Stroke	(OR,	95%	CI)	 0.88	(0.46,	16.5)	 0.81	(0.11,	5.92,	1.78)	 1.55	(0.54,	4.59)	 2.21	(1.24,	3.93)	
Dementia		
(OR,	95%	CI)	
0.98	(0.05,	18.5)	 0.96	(0.13,	7.09)	 2.10	(0.71,	6.20)	 2.48	(1.37,	4.47)	
Renal	failure		
(OR,	95%	CI)	
10.4	(1.80,	59.9)	 8.68	(2.25,	33.6)	 1.97	(0.46,	8.55)	 2.51	(1.06,	5.92)	
Duration	of	
hospitalization	
(expected	difference	in	
number	of	days)	
4.0	(3.2,	5.3)	 1.3 (1.02, 1.75) 	 0.27 (0.18, 0.407)	 2 (1.84, 2.13)	
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Figure	1:	PD	prevalence	rates	between	GP35	and	T1D	patients	
	
a)	stratified	by	age	group,	 	 	 	 b)	stratified	by	age	and	gender	
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Chapter	3	Discussion	
Over	the	past	decades,	significant	progress	has	been	made	on	discovering	the	genetic	origin	of	
disease	(Lill,	2016).	In	particular,	advances	have	been	made	in	understanding	the	genetic	
provenance	of	rare	diseases	with	highly	penetrant	traits	that	follow	Mendelian	inheritance	patterns.	
However,	much	remains	to	be	done	in	understanding	the	origins	of	complex	diseases	such	as	PD.	
Media	portrayal	of	famous	patients	such	as	Muhammad	Ali	or	Michael	J	Fox	have	increased	the	
disease	visibility,	with	traditional	portrayal	of	the	disease	as	neurodegenerative	characterized	by	
motor	symptoms.	PD,	however,	is	a	degenerative	disease	that	affects	much	more	than	just	the	
motor	systems.	Sensory,	digestive,	psychiatric,	and	urinary	systems	are	also	involved,	and	more	
recent	research	has	implicated	oxidative	stress	and	mitochondrial	dysfunction	not	simply	in	the	
brain	but	also	other	regions	of	the	body	as	a	part	of	disease	pathogenesis.	As	our	understanding	of	
PD	evolves,	it	is	more	accurate	to	consider	PD	as	a	degenerative	disease	affecting	multiple	systems,	
with	a	strong	neurological	component.	A	complex	disease	such	PD	has	also	a	complex	and	large	web	
of	genetic	risk-affecting	mutations	that	act	both	singularly	and	in	combination.	However,	much	
remains	to	be	done	to	elucidate	the	genetic	basis	of	PD.			
One	of	the	first	methods	used	to	determine	the	heritability	of	PD	was	twin	studies.	Given	the	shared	
childhood	environment	and	the	genetic	overlap	differences	between	monozygotic	versus	dizygotic	
twins,	it	is	possible	to	study	causality	of	genetic	factors	while	adjusting	for	the	possible	mediating	
effects	of	environmental	factors.	While	results	from	the	twin	studies	have	been	inconsistent,	
nevertheless	the	evidence,	though	not	statistically	significant,	pointed	towards	an	underlying	genetic	
etiology	for	PD	(Wirdefeldt	et	al.,	2011a).	Linkage	studies	using	large	multi-generational	families	
were	also	one	of	the	early	drivers	of	PD	genetics.	The	identification	of	the	first	PD-associated	
mutations	were	through	large	familial	kindreds.	Examples	include	the	autosomal	genes	SNCA,	
LRRK2,	DJ-1,	PINK1,	ATP13A2	and	PARKIN	discovered	through	familial	studies.	While	the	linkage	
approach	was	relatively	successful	for	identifying	highly	penetrant	but	rare	mutations,	the	majority	
of	PD	cases	are	sporadic,	with	only	10%	of	patients	reporting	a	positive	family	history	for	PD	
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(Thomas	and	Beal	2007).	As	study	sizes	increased,	GWAS	studies	became	sufficiently	powered	and	
thus	were	able	to	identify	26	independent	loci	that	modify	disease	risk,	including	genes	in	SNCA,	
MAPT,	GBA,	HLA,	and	GAK.		
Next-generation	sequencing	(NGS)	methods	such	as	exome	sequencing	identified	novel	mutations	in	
VPS35,	VPS13C,	CHCHD2,	and	DNAJC6	genes.	However,	the	vast	majority	of	PD	cases	is	still	sporadic	
with	unclear	etiology,	and	“missing	heritability”	continues	to	be	a	strong	theme	in	PD	genetics	even	
through	the	many	advancements	over	the	years.	With	the	advances	in	research,	our	understanding	
of	PD	has	evolved	from	a	single	system	neurodegenerative	disease	to	a	syndrome	encompassing	
mutiple	systems	as	well	(Titova	et	al.,	2017a).	Figure	1	illustrates	our	currently	knowledge	of	
penetrance	versus	frequency	of	genetic	risk	variants.		
Figure	7:	Penetrance	versus	Frequency.	X-axis	indicates	frequency	of	genetic	variants,	Y-axis	
indicates	penetrance	or	likelihood	of	disease	given	existence	of	mutation.		(Adapted	from	Lill	C,	
2016.	Mol	Cell	Probes).	
	
Due	to	the	complexity	of	the	genetic	architecture	of	PD,	it	is	hypothesized	that	the	resulting	
observed	PD	phenotype	comes	from	a	complicated	interplay	between	different	genes	with	each	
other	and	with	the	environment	and	life-style	of	the	person.	This	has	led	to	research	focusing	on	not	
just	simple	Mendelian	inheritance	patterns,	but	also	rare	variants,	gene-gene	interaction,	and	gene-
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environment	interactions.	The	repeatedly	observed	incomplete	penetrance	of	identified	genetic	risk	
variants	only	reinforce	the	theory	of	PD	as	a	multifaceted	and	multi-origin	neurodegenerative	
disease.		
One	of	the	common	threads	running	within	neurodegenerative	diseases	is	the	aggregation	of	
proteins	and	its	toxicity	towards	neural	tissue	(Goedert	et	al.,	2017).	In	1907,	Alois	Alzheimer	already	
noted	the	presence	of	neuritic	plaques	and	neurofibrillary	lesions	in	what	would	become	known	as	
Alzheimer’s	disease.	Subsequently,	Alzheimer	also	described	the	protein	aggregations	known	as	
“Pick	bodies”	that	are	characteristic	of	Pick’s	disease.	Lewy	later	described	in	1912	the	“Lewy	
bodies”	that	are	characteristic	of	PD.		
Aggregration	of	amyloidogenic	proteins	has	been	observed	in	molecular	pathways	associated	with	a	
wide	spectrum	of	neurodegenerative	diseases	including	AD,	PD,	and	dementia	(Ciryam	et	al.,	2013).	
AD	is	defined	by	deposits	of	tau	proteins,	and	deposits	of	fibrous	beta-amyloid	deposits	(Goedert	et	
al.,	2001).	It	is	the	most	famous	diseases	in	the	diverse	group	of	diseases	known	as	tauopathies,	
linked	by	the	degenerative	aggregation	of	tau	protein	inclusions.	Lewy	bodies,	protein	deposits	
strongly	immunoreactive	for	SNCA,	are	also	found	in	an	entire	class	of	neurodegenerative	diseases	
known	as	synucleinopathies	(Goedert,	2001).	The	discoveries	cemented	the	importance	of	protein	
aggregation	in	neurodegenerative	diseases.		
One	subset	of	neurodegenerative	diseases	with	protein	accumulation	are	the	polyglutamine	(polyQ)	
diseases.	Early	studies	showed	that	isolated	PolyQ	peptides	quickly	form	insoluble	amyloid	
aggregates	in	solution	and	linked	polyQ	repeated	expansions	to	neurodegeneration	(Chen	et	al.,	
2002).	Over	the	last	two	decades,	scientists	discovered	that	polyglutamine	(polyQ)	repeat-containing	
proteins	are	common	within	the	human	proteome.	These	include	huntingtin	in	Huntington’s	disease,	
ataxin-1,	ataxin-2,	ataxin-3,	voltage-dependent	calcium	channel	alpha-1A	subunit,	ataxin-7,	TATA-
binding	protein,	and	spinocerebellar	ataxia	1,	2,	3,	6,	7,	and	17.	In	particular,	spinocerebellar	ataxia	3	
	
	
87	
(Machado-Joseph	Disease)	is	the	second	most	common	PolyQ	disease	after	Huntington’s	disease	
(Riess	et	al.,	2008).		
Autosomal	dominant	cerebellar	ataxias	(ADCA)	is	a	group	of	rare	neurodegenerative	diseases	that	
primary	affect	the	motor	system,	though	mild	intellectual	deficits	are	also	observed	(Durr,	2010).	
Motor	degeneration	is	characterized	by	cerebellar	atrophy	and	neuronal	loss	in	the	spinocerebellar	
tracts,	with	coordination	problems,	loss	of	balance,	slurred	speech,	and	gait	disorders	commonly	
observed	(Schöls	et	al.,	2004).	The	diseases,	more	than	40	different	types	have	been	identified,	are	
heteregenous	both	clinically	and	genetically,	with	mutations	in	32	identified	genes.	While	the	
majority	of	mutations	are	repeat	expansions	(65%),	a	minority	is	also	caused	by	missense,	nonsense,	
and	truncations	(Durr,	2010).	Recently,	studies	have	linked	SCA	to	changes	in	the	synaptic	
transmission	and	transcription	regulation,	showing	these	mechanisms	to	be	commonly	attacked	
between	the	genetically	distinct	spinocerebellar	ataxias	(Nibbeling	et	al.,	2017).	Breakdown	in	the	
natural	autophagy	process	leading	to	pathological	protein	aggregation	was	also	observed	(Nibbeling	
et	al.,	2017),	a	common	trend	within	neurodegenerative	diseases.	
Emerging	evidence	in	neurodegeneration	has	provided	support	that	late-onset	neurodegenerative	
diseases	with	biologic	overlap	may	have	common	genetic	risk	factors	disease	even	though	they	
present	with	clinically	heterogeneous	symptoms	(Ross	et	al.,	2011,	Simon-Sanchez	et	al.,	2005).	In	
particular,	evidence	of	SCA-2	expansion	was	found	in	a	family	with	autosomal	dominant	Parkinson’s	
disease	and	families	with	SCA2	and	SCA3	expansions	presenting	with	typical	Parkinson’s	disease	
symptoms	(Furtado	et	al.,	2002,	Simon-Sanchez	et	al.,	2005,	Kim	et	al.,	2017).	SCA2	is	characterized	
by	repeated	CAG	triplets	in	the	N-terminal	region	of	the	protein	ataxin	2,	with	the	presence	of	more	
than	31	repeats	possibly	causing	clinical	neurodegeneration	(Ross	et	al.,	2011).	The	parkinsonism	
phenotype	has	also	been	observed	in	single	cases	in	patients	with	ATXN3	expansions	(Bettencourt	et	
al.,	2011).	Similarly,	atypical	Parkinsonism	and	PD-like	phenotypes	have	also	been	observed	in	SCA6	
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and	SCA17,	with	a	particular	number	of	studies	performed	within	the	Korean	ataxia	and	Parkinson’s	
scientific	community.		
A	recent	study	found	40	CAG	repeats	with	4	interruptions	in	the	PD	patients	of	a	Korean	family	
presenting	with	typical	physical	phenotype	of	autosomal	dominant	PD	without	cerebellar	ataxia	(Kim	
et	al.,	2017).		The	40	repeat	length	is	the	longest	observed	in	families	exhibiting	Parkinsonism	
without	ataxia.	There	is	considerable	debate	in	the	choice	of	cut-off	for	defining	“pathogenicity”	of	
repeats.	Using	a	multi-ethnic	cohort	as	discussed	in	Part	1	of	Chapter	2,	we	ascertained	our	cut-off	
threshold.	Our	own	allelic	density	plots	showed	comparable	distribution	of	repeat	length	between	
our	cohort	and	previously	published	studies	(Figure	e1,	pg.	43),	but	our	SCA2	repeat	length	ranged	
from	24	to	32,	much	shorter	than	the	40	observed	in	the	South	Korea	family.	On	the	other	hand,	we	
did	not	investigate	the	role	of	interrupted	repeats	on	PD,	thus	our	results	cannot	comment	on	the	
South	Korean	family	with	Parkinsonism.	However,	our	results	do	suggest	a	trend	effect	for	SCA2	in	
the	Asian	population.	In	conjunction	with	the	recent	familial	evidence	from	the	longitudinal	Korean	
study,	our	trend	results	suggest	a	connection	between	SCA2	and	PD	in	the	Asian	cohort	is	an	
important	topic	to	further	study.		
Synuclein	aggregation,	one	of	the	hallmarks	of	PD,	has	been	linked	to	mutations	in	the	cell	transport	
systems,	and	the	retromer	pathway	has	been	specifically	implicated	in	PD	pathogenesis	(Mohan	and	
Mellick,	2017).	VPS35	codes	a	part	of	the	retromer	complex	that	is	responsible	for	protein	sorting	
between	the	endosome-lysosome	degradation	pathways	and	the	Golgi	apparatus	(Bonifacino	and	
Hurley,	2008).	Mutations	in	the	VPS35	gene,	a	protein	integral	to	intracellular	retrieval	of	membrane	
proteins		in	the	retromer	pathway	has	been	linked	to	patients	with	autosomal	dominant	PD	
(Zimprich	et	al.,	2011,	Tang	et	al.,	2015b).	Furthermore,	mutations	in	VPS35	has	also	been	
demonstrated	to	result	in	alpha-synuclein	aggregation	in	animal	models	(Tang	et	al.,	2015a).		
A	series	of	studies	in	the	previous	years	demonstrated	functional	interaction	between	two	distinct	
loci	that	both	affect	the	functionality	of	the	VPS35	component	of	the	retromer	complex	(Chuang	and	
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Gitler,	2013,	MacLeod	et	al.,	2013).	From	there,	evidence	mounted	that	faulty	protein	sorting	within	
the	vesicle	components	was	tied	to	PD	pathogenesis	(Bonifacino	and	Hurley,	2008).	LRRK2	has	been	
implicated	repeatedly	as	a	PD	risk	gene	in	genetic	studies;	the	gene	codes	a	large	multi-domain	
protein	that	is	tied	to	GTPase	and	kinases	activities	(Webber	and	West,	2009).	Mutations	in	LRRK2	
damage	lysosomal	protein	degradation	and	autophagy,	thus	hindering	the	cellular	process	of	
delivering	protein	aggregates	and	cytosolic	proteins	to	the	lysosome,	the	structure	responsible	for	
breaking	down	biological	polymers	(Kuwahara	et	al.,	2016).	Thus	taken	together,	the	evidence	
suggests	a	strong	connection	between	defective	protein	sorting	and	vesicle	transport	and	PD	
pathogenesis.		
Interaction	studies	between	PD	risk-modifying	variants	has	been	of	particular	interest	in	PD	genetics,	
as	newly	discovered	genes	had	small	effects	on	the	total	“missing	heritability”	seen	in	PD.	Thus,	an	
open	question	is	the	degree	to	which	PD	genes	modulate	each	other	and	influence	the	effect	of	the	
singular	mutations.	A	previous	study	found	connections	and	synergistic	effects	between	VPS35	and	
EIF4G1	mutations	and	SNCA	toxicity	(Dhungel	et	al.,	2015).	Recent	research	has	already	
demonstrated	LRRK2	and	PARK16	functional	interaction.	Wildtype	VPS35	expression	has	been	
demonstrated	to	rescue	defects	in	the	endolysosomal	and	Golgi	apparatus	sorting	complex	caused	
by	RAB7L1	or	LRRK2	mutations	(MacLeod	et	al.,	2013).	In	the	same	study,	Macleod	et	al	also	
demonstrated	functionally	that	deficiency	of	the	PARK16	locus	gene	RAB7L1	synergistically	affected	
neurodegeneration	in	rodent	models	of	familial	PD	due	to	mutant	LRRK2	expression,	while	RAB7L1	
over-expression	rescued	the	LRRK2	mutant	phenotype.	RAB7L1	suppressed	LRRK2	mutant	pathology	
in	both	in	vitro	and	in	vivo	screenings.	
The	functional	studies	preceding	our	investigation	set	up	the	foundation	for	our	gene-gene	
interaction	study	between	PARK16	and	LRRK2.	While	there	is	a	consensus	that	genetic	interaction	
studies	are	generally	underpowered,	that	does	not	indicate	that	they	are	not	of	value.	Working	with	
the	constraints	of	availability,	we	conducted	the	largest	interaction	study	to	date	on	an	international	
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multi-ethnic	cohort.	The	functional	studies	on	the	interaction	between	PARK16	and	LRRK2	in	the	
retromer	pathway	argue	convincingly	of	a	biological	effect	(MacLeod	et	al.,	2013).	As	expected	with	
gene	interaction	studies,	our	study	failed	to	show	statistical	significance	of	interaction.	Nevertheless,	
we	observed	a	trend	for	interaction,	which	did	not	reach	significance	due	to	sample	size.	The	trend	
effect	is	observed	in	OR’s	between	concomitant	carriers	of	both	LRRK2	and	PARK16	versus	carriers	
of	only	LRRK2;	with	carriers	of	both	mutant	genotypes	at	significantly	lower	risk	of	PD	versus	LRRK2	
carriers	(Chapter	2	Part	3,	Supplementary	Table	2).	We	found	results	that	suggest	an	effect	in	the	
same	direction	as	previous	literature,	but	our	study	does	not	support	the	presence	of	a	strong	
interaction	effect.		
In	a	post-publication	analysis	of	the	data,	we	considered	the	possibility	that	certain	sites	with	
particularly	large	variance	covered	a	true	effect	of	interaction,	and	thus	performed	leave-one	out	
analysis	across	all	sites.	However,	the	results	did	not	change,	and	no	significant	interaction	effect	
was	observed	(Table	1).	This,	in	turn,	is	consistent	with	our	data	quality	screening	where	we	did	not	
observe	any	statistically	significant	heterogeneity	in	the	data.		
Table	15:	Post-hoc	Leave-one-out	analysis,	Site	column	indicates	dataset	that	was	withheld	
Sites	 OR	Coefficient	 95%	CI	 P-Value	
Aasly	 0.87	 (0.75,	1.02)	 0.085	
Annesi	 0.86	 (0.74,	1.01)	 0.064	
Bozi	 0.87	 (0.74,	1.01)	 0.071	
Belgium	 0.88	 (0.75,	1.03)	 0.125	
Brice	 0.87	 (0.74,	1.01)	 0.075	
Hadjigeorgiou	 0.87	 0.74,	1.02)	 0.087	
Lynch/Ross	 0.88	 (0.75,	1.03)	 0.105	
Maraganore	 0.87	 (0.74,	1.01)	 0.069	
Mellick	 0.87	 (0.75,	1.03)	 0.100	
Morrison	 0.85	 (0.72,	0.99)	 0.036	
Opala/Ross	 0.86	 (0.74,	1.01)	 0.066	
Wirdefeldt	 0.87	 (0.74,	1.01)	 0.071	
Wszolek/Ross	 0.86	 (0.74,	1.01)	 0.065	
Chung	 0.89	 (0.75,	1.05)	 0.171	
Lin	 0.88	 (0.85,	1.04)	 0.125	
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Japan	 0.76	 (0.62,	0.93)	 0.008	
Tan	 0.88	 (0.75,	1.04)	 0.128	
OR:	Odds	Ratio,	CI:	Confidence	Interval	
The	etiology	of	idiopathic	PD	has	proven	to	be	a	complex	and	difficult	to	untangle	interconnected	
web	of	aging,	environmental,	and	genetic	factors.	In	addition	to	protein	aggregation	and	defects	in	
the	transport	pathways,	mitochondrial	dysfunction,	oxidative	stress	and	neuroinflammation	have	
also	come	under	consideration	as	etiological	factors	for	PD	(Lee	et	al.,	2017).	Pathology	in	brains	of	
PD	and	DLB	patients	versus	healthy	controls	found	that	brain	cortex	activity	and	mitochondrial	O2		
uptake	were	significantly	lower	in	diseased	patients,	and	signs	oxidative	stress	and	mitochondrial	
dysfunction	were	significantly	higher	in	diseased	patients	(Navarro	and	Boveris,	2009).	Within	PD	
neuropathogenesis,	research	has	also	found	evidence	that	microglial	activation	causes	increased	
activity	in	the	cyclooxygenase	(COX)	pathway	(Tansey	et	al.,	2007).	Furthermore,	anti-inflammatory	
treatment	protected	against	dopaminergic	cell	death	and	blocked	activation	of	microglial	cells	in	the	
MPTP-induced	mouse	model	of	PD	(Kim	et	al.,	2012).		
Inflammation	is	a	shared	manifestation	of	pathogenesis	observed	in	both	PD	and	auto-immune	
diseases.	Genetic	pleiotropy,	the	idea	that	a	single	gene	has	multiple	different	manifestations	
through	its	functionality	within	separate	biological	pathways,	has	also	been	a	growing	theme	in	
genetic	research.	A	study	from	2016	used	GWAS	data	to	identify	a	common	mutation	in	the	
extended	MAPT	region	that	is	associated	with	both	AD	and	PD	(Desikan	et	al.,	2015).	Outside	of	
pleiotropy	between	neurodegenerative	diseases,	common	genetic	variants	have	also	been	
established	between	PD	and	auto-immune	diseases.	Crohn’s	disease	has	also	identified	LRRK2	as	a	
susceptibility	loci	uses	GWAS	(Franke	et	al.,	2010).	Additionally,	SNCA	has	been	identified	in	the	
enteric	neurons	in	the	myenteric	plexus	situated	within	the	gastrointestinal	tract	(Sharrad	et	al.,	
2013).	Research	has	found	that	mitochondrial	dysfunction	and	inflammation,	a	common	theme	
between	PD	and	autoimmune	diseases,	is	a	potential	shared	byproduct	of	immune	dysfunction	
(McGeer	and	McGeer,	2011).	Pleiotropic	genes	have	also	been	identified	between	AD	and	T1D	
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(Christensen	et	al.,	2016).	On	the	other	side	of	this	growing	body	of	evidence,	human	leukocyte	
antigen	(HLA),	a	major	histocompatibility	complex	tied	to	immune	dysfunction	and	autoimmune	
diseases,	has	also	emerged	as	an	important	risk	loci	for	PD	(Witoelar	et	al.,	2017,	Wissemann	et	al.,	
2013).	Associations	between	AD	and	immune-mediated	diseases	has	also	been	demonstrated	
(Yokoyama	et	al.,	2016).	Candidate	gene	studies	assessing	genetic	variable	have	found	that	
neuroinflammatory	genes	such	as	TNF,	IFN-gamma,	and	IL	also	increase	risk	of	PD.		
Given	the	emerging	evidence	of	immune	dysfunction	and	neuroinflammation	in	neurodegenerative	
diseases,	and	in	particular	PD,	we	looked	at	connections	between	PD	and	Type	1	Diabetes,	a	disease	
with	a	very	strong	auto-immune	component.	Connections	between	PD	and	T1D	goes	beyond	the	
HLA	connection.	Alpha-synuclein	deposits	have	been	discovered	in	the	pancreas	of	PD	patients	
(Titova	et	al.,	2017a).	Autoimmune	diseases	such	as	T1D	are	also	tied	to	many	of	the	same	
inflammatory	mediators,	and	it	has	been	suggested	that	the	immune	response	from	mediators	such	
as	cytokines	not	also	contribute	to	cell	death	and	disease	pathogenesis	of	the	autoimmune	disease,	
but	also	increases	the	risk	as	well	of	neurodegenerative	diseases.	With	the	development	of	evidence	
on	not	only	genetic	risk	factors	but	also	disease	pathogenesis,	we	performed	a	comparison	study	
between	the	prevalence	and	diabetic	end-points	of	neurologically	normal	T1D	patients	and	patients	
with	PD.		
We	found	evidence	that	supports	the	emerging	relationship	between	PD	and	T1D.	Our	findings	on	
the	differences	in	renal	function	are	very	interesting	in	light	of	the	discovery	of	alpha-synulcein	
deposits	outside	of	the	brain	in	PD	patients.	With	the	discovery	of	alpha-synuclein	deposits	in	the	
pancreas	of	PD	patients,	the	increased	risk	of	renal	failure	in	PD	patients	is	even	more	interesting	
given	the	knowledge	that	PD	does	affect	organs	outside	of	the	brain.	We	also	observed	differences	
in	rates	of	stroke	and	dementia	between	PD	patients	and	neurologically	normal	patients.	Stroke	has	
been	tied	to	inflammation	and	hypertension,	two	symptoms	also	related	to	PD	pathogenesis.	
Diabetes	and	PD	both	see	increased	rates	of	dementia	within	its	patient	population,	and	the	
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increased	rate	at	which	PD	T1D	patients	presented	with	dementia	raises	the	question	of	whether	it	
is	a	manifestation	resulting	from	common	genetic	etiology	between	two	diseases.		Thus,	it	warrants	
further	study	to	understand	the	genetic	etiology	of	dementia	and	its	ties	to	both	PD	and	T1D.		
Future	perspectives	and	directions	
PD	affects	the	quality	of	life	of	patients,	caregivers,	and	consequently	the	national	health	economies	
through	lost	productivity.	As	the	world	population	ages,	its	impact	will	only	increase.	One	of	the	keys	
to	treating	and	targeting	PD	is	through	a	better	understanding	of	its	risk	architecture.	With	that	in	
mind,	the	underlying	aim	in	this	thesis	is	to	advance	the	understanding	of	risk	factors	of	PD.		
With	the	research	presented	here,	we	have	not	only	contributed	to	the	current	body	of	knowledge,	
but	also	have	highlighted	important	avenues	of	future	research.	In	particular,	while	the	ataxia	study	
and	the	interaction	study	were	negative	studies,	they	nonetheless	contributed	substantially	to	the	
general	conversation.	Clinicians	now	know	that	it	is	not	necessary	to	screen	for	PD	in	patients	with	
the	aforementioned	ataxia	types.	In	the	case	of	the	LRRK2	PARK16	interaction	study,	we	
demonstrated	that	it	is	unlikely	that	a	strong	synergistic	or	negating	effect	exists	between	the	two	
genes,	but	also	highlighted	the	need	for	substantially	larger	studies,	particularly	in	the	context	of	
gene-gene	statistical	interaction.		
PD	is	a	complicated	illness,	with	many	environmental	and	genetic	risk	factors	and	a	diverse	web	of	
non-motor	and	motor	symptoms.	It	shares	pathology	with	numerous	other	neurodegenerative	
diseases.	Furthermore,	the	role	of	the	auto-immune	system	also	bears	future	exploration,	as	
demonstrated	by	our	diabetes	study,	among	others.	Science	rarely	comes	from	large	leaps,	instead	
one	can	only	reach	the	next	set	of	stars	by	first	standing	on	the	shoulders	of	giants,	of	those	who	
have	gone	before	us.	The	epidemiology	of	Parkinson’s	disease	is	no	exception	to	this	old	adage	by	
Newton.	Our	ultimate	goal,	as	researchers,	is	to	fully	understand	the	genetic	landscape	of	PD.	
However,	one	can	only	poke	holes	into	the	darkness,	chipping	away	at	this	complex	task,	one	study	
at	a	time,	one	piece	of	research	at	a	time.	
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Chapter	4	Summary	
English	Summary		
PD	is	the	second	most	common	neurodegenerative	disease	in	the	world,	with	the	disease	burden	
only	expected	to	rise	as	the	world	population	ages.	The	discovery	of	new	genetic	risk	factors	through	
a	range	of	methods	over	the	years	has	resulted	in	a	long	list	of	genetic	variants	that	influence	PD	
risk.	However,	our	understanding	of	the	genetic	variants	and	the	mechanisms	through	which	they	
influence	PD	risk	still	leave	much	room	for	future	discovery.	The	incompleteness	of	the	inheritance	
patterns	and	the	limited	ability	(up	to	10%)	of	the	genetic	variants	to	explain	PD	cases	suggests	
complex	and	multifactorial	origins	for	PD.	Hence,	this	thesis	seeks	to	fill	some	of	the	open	questions.		
The	first	part	of	the	thesis	addresses	the	etiological	factor	of	protein	aggregation	through	the	
question	of	cross-disease	effect	of	ataxia	genes	on	PD	risk.	We	did	not	find	any	increase	in	in	PD	risk	
in	relation	to	the	existence	of	intermediate	repeat	expansions	in	SCA2,	3,	6,	and	17	in	a	large	scale	
consortium	study,	and	thus	no	evidence	that	the	familial	affect	seen	extrapolates	to	sporadic	PD.	
	The	second	part	of	the	thesis	takes	the	theme	of	aggregration	but	approaches	it	from	the	
transportation	pathways.	Given	the	known	functional	interaction	between	two	genes	in	the	
retromer	pathway,	we	also	investigate	a	possible	genetic	interaction	between	the	two	previously	
identified	risk	modulating	loci,	PARK16	and	LRRK2.	Using	a	large	scale	multi-site	study,	we	did	not	
find	any	conclusive	evidence	of	strong	genetic	interaction	between	the	two	loci.	However,	our	
results	suggest	that	further	research	is	needed	with	larger	sample	sizes,	due	to	our	trend	findings	
within	subgroups	of	our	population.		
Immune	response	and	mitochondrial	dysfunction	drive	the	third	part	of	the	thesis;	we	investigate	
the	differences	in	clinical	outcomes	between	type	1	diabetic	patients	with	PD	and	neurologically	
normal	patients.	Recent	studies	have	demonstrated	the	sharing	of	pathways	and	commonalities	in	
pathogenesis	between	the	two	diseases	due	to	shared	auto-immune	dysfunction,	along	with	the	
discovery	of	HLA	as	a	risk	loci	for	both	diseases.	Due	to	the	interconnectedness	of	the	two	disease,	
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we	felt	it	was	important	to	also	study	the	clinical	pathogenesis	of	PD	patients	within	a	T1D	
population.	We	found	several	significant	differences	in	T1D	patients	with	and	without	PD,	mainly	
renal	failure,	stroke,	and	hospitalizations,	suggesting	that	a	correlation	between	PD	and	certain	
diabetic	outcomes.		
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Chapter	6	German	Summary	
	
Parkinson-Krankheit	ist	die	zweithäufigste	neurodegenerative	Krankheit	in	der	Welt,	wobei	die	
Krankheitslastmit	steigender	Weltbevölkerung	nur	steigen	wird.	Die	Entdeckung	neuer	genetischer	
Risikofaktoren	durch	eine	Reihe	von	Methoden	im	Laufe	der	Jahre,	hat	zu	einer	langen	Liste	von	
genetischen	Varianten	geführt,	die	das	PD-Risiko	beeinflussen.	Unser	Verständnis	der	genetischen	
Varianten	und	der	Mechanismen,	durch	die	sie	das	PD-Risiko	beeinflussen,	lässt	jedoch	noch	viel	
Raum	für	zukünftige	Entdeckungen.	Die	Unvollständigkeit	der	Vererbungsmuster	und	die	begrenzte	
Fähigkeit	(bis	zu	10%)	der	genetischen	Varianten,	PD-Fälle	zu	erklären,	deuten	auf	komplexe	und	
multifaktorielle	Ursachen	für	PD	hin.	Daher	versucht	diese	Arbeit	einige	der	offenen	Fragen	zu	
beantworten.	
Der	erste	Teil	der	Arbeit	befasst	sich	mit	dem	ätiologischen	Faktor	der	Proteinaggregation	durch	die	
Frage	der	Kreuz-Krankheit-Wirkung	von	Ataxie-Genen	auf	PD-Risiko.	In	einer	groß	angelegten	
Konsortium	Studie	fanden	wir	keinen	Anstieg	des	PD-Risikos	in	Bezug	auf	die	Existenz	von	
repetitiven	Zwischenexpansionen	in	SCA2,	3,	6	und	17,	und	somit	keinen	Hinweis	darauf,	dass	der	
beobachtete	familiäre	Affekt	sich	auf	die	sporadische	Parkinson-Krankheit	ableiten	lässt.	
Der	zweite	Teil	der	Arbeit	behandelt	das	Thema	Aggregation,	nähert	sich	aber	von	seiten	der	
Transportpfade.	Angesichts	der	bekannten	funktionellen	Interaktion	zwischen	zwei	Genen	im	
Retromer-Signalweg	untersuchen	wir	auch	eine	mögliche	genetische	Interaktion	zwischen	den	
beiden	zuvor	identifizierten	Risiko-modulierenden	Loci,	PARK16	und	LRRK2.	In	einer	großen	
multizentrischen	Studie	fanden	wir	keine	schlüssigen	Beweise	für	eine	starke	genetische	Interaktion	
zwischen	den	beiden	Loci.	Unsere	Ergebnisse	deuten	jedoch	darauf	hin,	dass	aufgrund	unserer	
positiven	Trends	in	Subgruppen	unserer	Population	weitere	Untersuchungen	mit	größeren	
Stichproben	erforderlich	sind.	
Immunantwort	und	mitochondriale	Dysfunktion	bestimmen	den	dritten	Teil	der	These;	Wir	
untersuchen	die	Unterschiede	in	den	klinischen	Ergebnissen	zwischen	Typ-1-Diabetikern	mit	PD	und	
neurologisch	normalen	Patienten.	Jüngste	Studien	haben	geteilte	Stoffwechselwege	und	
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übereinstimmende	Pathologien	zwischen	beiden	Krankheiten,	die	auf	eine	gemeinsame	
Autoimmunfunktionsstörung	zurückzuführen	sind,	gezeigt	und	gleichtzeitg	HLA	als	Risiko-Loci	für	
beide	Erkrankungen	entdeckt.	Aufgrund	der	Vernetzung	der	beiden	Erkrankungen	war	es	uns	
wichtig,	auch	die	klinische	Pathogenese	von	PD-Patienten	innerhalb	einer	typ	1	Diabetes	Population	
zu	untersuchen.	Wir	fanden	mehrere	signifikante	Unterschiede	bei	T1D-Patienten	mit	und	ohne	PD,	
hauptsächlich	Nierenversagen,	Schlaganfall	und	Krankenhauseinweisungen,	was	auf	eine	Korrelation	
zwischen	PD	und	bestimmten	diabetischen	Ergebnissen	hindeutet.	
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